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ABSTRACT 
 
Secoisolariciresinol (SECO) is the major lignan present in flaxseed,
1-3
 but unlike the structurally 
related lignan nordihydroguaiaretic acid, it is not associated with toxicity.
3-5
  The major phase I 
metabolite of SECO is lariciresinol, likely formed as a result of para-quinone methide (p-QM) 
formation followed by an intramolecular cyclization, thereby minimizing any toxicity associated 
with the p-QM.
2
 Four analogues of SECO were used to investigate substituent effects on lignan 
metabolism and formation of reactive quinones. 
 
HPLC methods were developed for analysis of SECO analogues and their metabolites. The 
stability of SECO analogues (1 mM) in a 50 mM Na2HPO4 buffer at pH 6.0 and 7.4 were 
quantified. Enzymatic oxidation experiments using mushroom tyrosinase and microsomes 
harvested from male Sprague-Dawley rats were performed with and without a GSH trapping 
system. Mass spectrometry and LC-MS were used to identify metabolites. Life Technologies was 
contracted to perform IC50 inhibition assays on SECO and the SECO analogues against 
CYP3A4, CYP3A5, CYP2C9 and CYP2C19 cytochrome P450 isoforms. 
 
All SECO analogues were stable at pH 6.0. SECO-2 was stable at pH 7.4 but SECO-1, -3 and -4 
were unstable at pH 7.4. Autoxidation of SECO -1, -3 and -4 were 1
st
 order reactions with t1/2 of 
9.0 h, 1.7 h and 7.0 h respectively. Mushroom tyrosinase oxidations were performed to generate 
ortho-quinone standards. SECO-1 -3 and -4 were oxidized by mushroom tyrosinase but SECO-2 
was not. Trapping with GSH produces aromatic ring conjugates for SECO-1, -3, -4. Results from 
microsomal oxidations for SECO-1, -3 and -4 are consistent with these standards. SECO-2 was 
metabolized by a microsomal system to produce a benzyl GSH adduct. Dealkylation products 
were also observed. All SECO analogues formed quinones but interestingly, GSH conjugation 
was competitive with intramolecular cyclization. All cytochrome P450 isoforms were inhibited 
by every analogue tested to varying degrees, a potential cause of toxicity concerns.  
 
Quinones are known to cause toxicity in vivo, including cytotoxicity, immunotoxicity, and 
carcinogenesis. Our results suggest that since the phenol and catechol lignans form GSH adducts 
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in addition to intramolecular cyclization products, this class of lignans have the potential to cause 
toxicity.  
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1.0 Introduction 
Many Canadians are turning to natural products as alternatives to pharmaceutical drugs, and 
believe that natural products are safer than chemical products or pharmaceutical drugs according 
to a recent study.
1
 This belief remains, despite the lack of scientific data on their toxicity and the 
absence of strict regulations present for pharmaceuticals.
2
 At the same time the number of North 
Americans taking multiple medications at the same time is on the rise, increasing the chances of 
drug-drug interactions, which can lead to the occurrence of dangerous toxicological effects.
3
  
 
The toxicity of many chemicals is linked to their metabolism. Metabolism can lead to the 
formation of reactive intermediates, which can either react covalently with cellular 
macromolecules or generate reactive oxygen species (ROS) causing oxidative stress.   Metabolic 
drug-drug interactions can cause changes on the scale of an order of magnitude or more in blood 
and tissue concentrations of a drug or metabolite. This can in turn affect the extent to which toxic 
or active metabolites are formed. Large changes in drug or active metabolite exposure can alter 
its safety and efficacy profile. Changes in exposure are always a concern but are especially 
significant when a drug has a narrow therapeutic range.
4
  
 
Flax (Linum usitatisimum L)
5
 has been farmed since 7000 BC but today a great deal of interest in 
flax stems from its potential health benefits and the increased presence of flaxseed in the human 
diet.
6
 Flaxseed’s potential health benefits may be due to natural products called lignans,7 as 
flaxseed is one of the richest known sources of lignans. Interest in lignans and their use as a 
natural product, arose from associated beneficial changes in blood lipid profiles, antioxidative 
effects and estrogenic, antiviral, antiestrogenic and anticarcinogenic activities.
6,8-12
 
Secoisolarisiresinol diglucoside (SDG) is the major lignan in flaxseed, where it is found in levels 
greater than 100 times those in other food sources, such as bramble, soy beans, garlic and tea.
13
 
SDG is hydrolyzed to secoisolarisiresinol (SECO), in the mammalian gastrointestinal tract.
2-4
  
 
Some putative health benefits of SECO include reduction in serum cholesterol levels, delaying 
the onset of type II diabetes, the treatment/prevention of cardiovascular diseases and decreased 
formation of breast, prostate and colon cancers.
9,10
 SECO has also been found to be an anti-
 2 
 
oxidative phenolic lignan, efficient at protecting cells in vitro from oxidative damage, which 
increases SECOs value as a therapeutic agent.
10
 SECO undergoes oxidative metabolism to a 
para-quinone methide (p-QM) in both rat and human hepatic microsomes.
3
 The major metabolite 
of SECO from hepatic microsomal studies is lariciresinol, which is likely formed as a result of p-
QM formation followed by an intramolecular cyclization thereby minimizing any toxicity 
associated with formation of the p-QM.
3
 Therefore SECO, unlike the structurally related 
nordihydroguaiaretic acid (NDGA), is not associated with toxicity.
1,4,5
  
 
Quinones can have various toxicological effects in vivo, including cytotoxicity, immunotoxicity, 
and carcinogenesis.
14
 Quinones are highly reactive compounds as they are both oxidants and 
electrophiles.
15
 Covalent binding can cause cytotoxicity if the electrophilic quinones react with 
nucleophilic groups on cellular macromolecules like thiol and amine groups in proteins and 
DNA. Quinones are also potent redox active compounds, which can undergo redox cycling with 
their semi-quinone radicals, generating reactive oxygen species (ROS) and leading to oxidative 
stress through the formation of oxidized cellular macromolecules, including: lipids, proteins and 
DNA.
14,16 
 
Several analogues of SECO (SECO-1,2,3,4) with altered functional groups were previously 
synthesized and will be used to investigate substituent effects on: lignan metabolism and 
formation of reactive quinones and to probe the effect of structure on the pharmacological and 
toxicological properties of SECO. 
2.0 Literature Review 
2.1 Natural Health Products 
Natural health products (NHPs) are naturally occurring substances used to restore or maintain 
good health.
17
 NHPs are often made from plants, but can also be made from other sources 
including animals and microorganisms.
18
 NHPs include: vitamins and minerals, herbal remedies, 
homeopathic medicines, traditional medicines like traditional Chinese and Ayurvedic (East 
Indian) medicines, probiotics and other products like amino acids and essential fatty acids.
19
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NHPs are sold in a wide variety of forms including: tablets, capsules, tinctures, solutions, 
creams, ointments and drops.
19
 NHPs are marketed for an assortment of different health concerns 
such as: the prevention or treatment of an illness or condition, reduction of health risks and the 
maintenance of overall optimal health.
19
 Canadians that consume NHPs do so for a variety of 
reasons but according to a 2010 survey the top reasons are health maintenance (85%), illness 
prevention and strengthening one’s immune system (79%) and general concern about one’s 
health (76%).
1
 
 
2.1.2 Canadian use of NHPs 
Many Canadians (73%) have used natural health products and a large proportion of Canadians 
(71%) indicate they believe NHPs are better for them than chemical products or pharmaceutical 
drugs,
1
 however just because a product is natural does not mean that it is safe.
2,17,20
 There is a 
general perception among Canadians that products derived from natural sources are safe to use. 
Encouragingly, consumer awareness of the possible dangers is growing; the percentage of 
Canadians who indicated natural products are safe decreased from 52% in 2005 to 42% in 2010.
1
 
Of the Canadians who use NHPs, 15% reported adverse reactions to Health Canada and 41% of 
individuals who experienced an adverse reaction reported it;
1,19
 meaning the percentage of 
Canadians who experience adverse reactions from NHPS is closer to 24%. This percentage of 
voluntary reports is unusually high for a voluntary reporting system. It is well documented in the 
literature that under reporting of adverse events or adverse drug events occurs in voluntary 
reporting systems with only about 5% of incidences reported.
21-24
 Unlike pharmaceuticals, which 
must have their physicochemical properties fully characterized before clinical development or 
marketing, NHPs are not subject to the same scrutiny and regulations.
2,17
 This less stringent 
regulatory requirement is an issue, as many Canadians do not scrutinize NHPs the way they do 
pharmaceuticals. The inherent toxicity of NHPs, contamination, adulteration, misidentification 
and interactions with other natural products or pharmaceutical drugs can contribute to the 
potential harm of natural products.
20
 Regulations on the safety of these products rely both on the 
assessment of reported cases of adverse reactions and on published toxicity information. 
Unfortunately, there is a lack of scientific information on the toxicity of natural products and 
their constituents including metabolites.
20
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2.1.3 Natural and Non-prescription Health Products Directorate (NNHPD) 
NHPs are regulated under the Natural and Non-prescriptive Health Products Directorates 
(NNHPD) formerly the Natural Health Products Directorate (NHPD) under the Natural Health 
Products Regulations which came into effect in 2004 under the Food and Drugs Act.
18
 All NHPs 
must have a product license to be legally sold in Canada.
18
 If a product has been licensed it will 
have either a Natural Product Number (NPN) or a Homeopathic Medicine Number (DIN-HM) 
on the label. Canadian sites that manufacture, package, label and import NHPs must also have a 
license.
18
 Health Canada has issued over 70,000 NHP product licenses and over 2,000 site 
licenses since 2004 when these regulations came into effect.
18
 One caveat to these regulations is 
that they only pertain to Canadian stores and websites. Non-Canadian websites are not covered 
under these regulations. When a google search was conducted on November 12, 2015 for 
“Echinacea, purchase”, 9 out of the first 10 hits were non-Canadian sites.   
 
2.2 Flaxseed 
2.2.1 A brief history of flax 
Flax (Linum usitatisimum L)
5
 has been farmed since 7000 BC and has been used in bread since 
1000 BC, but today interest in flaxseed stems from its potential health benefits and its increased 
presence in the human diet.
6
 Flax is an oilseed crop predominantly grown in the cooler regions of 
the world
25
 and was first brought to Canada in 1617 by Louis Hébert.
26
 Canada is now the 
world’s largest producer and exporter of flax with Saskatchewan growing approximately 85% of 
Canada’s flax.  
 
2.2.2 Canadian flaxseed 
Flaxseed is an oilseed whose seed mass is 32-45% oil with α-linolenic acid (an essential omega-3 
fatty acid) comprising approximately 51-55% of the oil.
27
 In 2014, Canadian farmers seeded 
 5 
 
628,000 hectares of land with flax yielding approximately 1,400 kg/hectare or a total of 846,000 
metric tonnes.
28
 The 2014 harvest had an average oil content of 45.6% and an average protein 
content of 21.1%. The main cause of the fluctuation in protein and oil content as well as oil 
composition within a variety are environmental factors related to growing conditions.
28
 Long-
term harvest samples collected by the Canadian Grain Research Laboratory show that crops 
grown in Canada also contains high levels of dietary fiber.
28
  
 
2.3 Lignans 
Though lignans are found in most fiber rich plants and legumes, flaxseed is one of the richest 
known sources of lignan.
5,6
 Lignans are an important class of secondary plant metabolites that 
consist of two phenylpropanoid units (Figure 2.1) formed by the coupling of two coniferyl 
alcohol residues present in the plant cell wall and are widely distributed in the plant kingdom.
5
  
       
Figure 2.1 Structures for C6C3 phenylpropane subunit (left) and basic lignan skeleton 
(right) 
 
As lignans present an enormous diversity in structure they have been classified into different 
families.
7,8
 The difference between plant and mammalian lignans (Figure 2.2) is that mammalian 
lignans have hydroxyl groups at the 3' position while plant lignans have oxygenated substituents 
at the 3' and 4' positions.
5
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Figure 2.2 Structures of an example of a mammalian lignan, enterodiol (ED; left) and plant 
lignan, matairesinol (right) 
Interest in lignans and their use as natural products, arose from numerous studies indicating their 
putative beneficial changes in blood lipid profiles, antioxidative effects and estrogenic, antiviral, 
antiestrogenic and anticarcinogenic activities.
6,8-12
  
 
2.3.1 Secoisolariciresinol diglucoside 
Secoisolariciresinol diglucoside (SDG), whose structure is shown in Figure 2.3, is the major 
lignan component in flaxseed.  
 
 
Figure 2.3 Structure of Secoisolariciresinol diglucoside (SDG) 
The SDG content of whole flaxseed is between 6.1 – 13.3 mg/g of whole flaxseed.29 Flaxseed 
contains greater than 100 times the levels of SDG as other food sources, such as bramble, 
soybeans, garlic and tea.
13
 Importantly, the majority of the plant lignans are located in the 
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aleuronic layer of the seed coat, thus milled flaxseed often has a low lignan content,
13
 and 
ingestion may not provide all the benefits associated with flaxseed use.  
 
2.4 Secoisolariciresinol 
2.4.1 Physical properties of SECO 
SDG undergoes acid catalyzed and -glycosidase-mediated hydrolysis to its aglycone form, 
secoisolariciresinol ([2R*,3R*]-2,3-Bis[4-hydroxy-3-methoxybenzyl]-1,4-butanediol; SECO; 
Figure 2.4) in the mammalian gastrointestinal tract. 
6,9-12
  
 
 
Figure 2.4 Structure of secoisolariciresinol 
SECO is a solid at room temperature with a molecular formula C20H26O6 and has a molecular 
weight of 362.42 g/mol.
30
 SECO is classified as a dibenzylbutane lignan and is an antioxidant.
31
 
Benzylic hydrogen abstraction at the 3-methoxy-4-hydroxyl substituents and potential resonance 
stabilization is thought to be the source of SECO’s antioxidant activity. 7,32  
 
2.4.2 Pharmacokinetic parameters of SECO 
SECO can be further metabolized to enterodiol (ED) and enterolactone (EL) (Figure 2.5) in the 
intestine or absorbed through the intestinal epithelia.
10
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Figure 2.5 From left to right the structures of secoisolariciresinol diglucoside, 
secoisolariciresinol, enterodiol and enterolactone as a result of human intestinal 
metabolism. 
 
In male Wistar rats the oral bioavailability of SECO is 26% and SECO was present in the 
systemic circulation for at least 21 h with evidence of enterohepatic recirculation.
33
 SECO is a 
reversible inhibitor of the drug metabolizing enzyme family CYP3A (concentration-dependent 
but not time-dependent manner) and induces the activity of the drug metabolizing family 
CYP2B.
2
  
 
SECO undergoes phase I oxidative metabolism in both rat and human hepatic microsomes and 
SECO may be oxidized to a para-quinone methide (p-QM; Figure 2.6).
10
 The major metabolite 
of SECO from hepatic microsomal studies is lariciresinol, which is likely formed as a result of p-
QM formation followed by an intramolecular cyclization, thereby minimizing any toxicity 
associated with formation of the p-QM (Figure 2.6).
10
 
 
 
Figure 2.6 SECO oxidation and intramolecular cyclization to lariciresinol. 
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2.4.3 Pharmacological properties of SECO 
Some putative health benefits of SECO include a reduction in serum LDL and total cholesterol 
levels, delaying the onset of type II diabetes, the treatment/prevention of cardiovascular diseases 
and decreased formation of breast, prostate and colon cancers.
9,10
 Of particular interest is the use 
of SECO as a protective agent against hormone dependent cancers, especially breast and prostate 
cancers.
9
 One in nine (1/9) Canadian women will be diagnosed with breast cancer in her lifetime 
and one in twenty nine (1/29) will die from it. Prostate cancer represents 24.5% of all new male 
cancer cases and everyday 11 Canadian men die from prostate cancer.
34
 SECO has been found to 
demonstrate antioxidant activity, and is efficient at protecting cells in vitro from oxidative 
damage, which increases SECO’s potential value as a therapeutic agent.9,10 
 
2.5 Nordihydroguaiaretic acid (NDGA) 
Nordihydroguaiaretic acid (NDGA; Figure 2.7) is closely related structurally to SECO. However, 
unlike SECO, NDGA is associated with toxicity.
7,8,35
 
 
Figure 2.7 Structure of nordihydroguaiaretic acid. 
2.5.1 Traditional uses of NDGA 
NDGA is found in the leaves of the creosote bush (Larrea tridentata) also known as chaparral or 
greasewood in the United States and as gobernadora or hediondilla in Mexico.
36
 The creosote 
bush can be found in the southwestern United States and the desert areas of Mexico.
37
 Chaparral 
tea made from resinous extracts of the creosote bush, containing NDGA, has been used for 
centuries by Native North Americans to treat a wide verity of illnesses, including: chicken pox, 
skin sores, diabetes, kidney and gallbladder stones, venereal disease, tuberculosis, colds, and 
rheumatism.
36,37
 NDGA has promising applications in the treatment of multiple diseases 
including the inhibition of tumors in historical reports as well as in vitro and animal studies.
36
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2.5.2 NDGA: Chemical properties 
NDGA is unstable in aqueous media at physiological pH (pH 7.4; t1/2 = 3.1 h). In the presence of 
O2, NDGA undergoes an autoxidation reaction and forms an ortho-quinone,
35
 which can be 
trapped as a glutathione (GSH) conjugate and is consistent with the observed increase in 
oxidative stress. In the absence of a trapping agent an intramolecular cyclization can occur to 
form a dibenzocyclooctadiene lignan (Figure 2.8)
35
 that may be responsible for some of the 
biological effects of NDGA, although the half-life of the dibenzocyclooctadiene (41 h) is 
comparable to the parent compound.
38
  
 
 
Figure 2.8 Structure of NDGA dibenzocyclooctadiene (cyclicNDGA). 
Curiously, NDGA does not appear to form the expected p-QM in the process of forming the 
dibenzocyclooctadiene lignan.
39
 It seems that spontaneous intramolecular cyclization to a 
dibenzocyclooctadiene requires a di-catechol lignan, which opens the possibility that this process 
may not be dependent on quinone formation.
39
 
 
2.5.3 Pharmacological properties of NDGA  
Numerous different pharmacological applications of NDGA have been studied, notably its anti-
inflammatory and anti-cancer properties, which have been reviewed by Lambert, J. et al. 2004, 
Arteaga, S. et al. 2005 and Lu, JM et al. 2010.
40-42
 NDGA is a strong antioxidant and a potent in 
vitro scavenger of reactive oxygen species (ROS).
37
 It has been demonstrated that NDGA has 
benefits in areas of cancer chemoprevention, cancer therapy, antimicrobial, fertility and 
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hypoglycaemic effects in in vitro and in vivo studies as well as human clinical trials.
41
 In 1992 
Actinex
®
 (Chemex Pharmaceuticals, Denver CO), a topical formulation of NDGA, was approved 
by the FDA for treatment of actinic keratosis,
43
 however Actinex
®
 was voluntarily withdrawn 
from the U.S. market in 1996 due to reports of skin hypersensitivity.
44,45
 NDGA is an inhibitor of 
CYP1A2
37
 and a potent inhibitor of lipoxygenase,
44,46
 HPV,
42
 HSV and HIV.
41,44
 The use of 
NDGA in a clinical setting however, is limited due to reports of its toxicity. 
 
2.5.4 NDGA toxicity 
Chronic exposure (260 – 3800 mg/day over several months)47 to chaparral is known to cause 
liver damage. Chronic consumption of chaparral tea is associated with drug-induced hepatitis
46
 
and cystic renal disease.
48
 There is one reported case of total liver failure
46,49
 and several cases of 
cirrhosis of the liver.
46
 When the use of Chaparral was discontinued the symptoms of 
hepatotoxicity were reversed.
42,46,49,50
 In humans, high doses of NDGA (for example 160 mg/d 
for 2 months) are associated with dermatitis, nephrotoxicity, biliary toxicity and hepatotoxicity 
including fulminant liver failure, and renal cell carcinoma.
37
  
 
The Meat Inspection Division of the US War Food Administration initially approved NDGA for 
commercial use in 1943 as a food antioxidant to preserve fats and butter.
37
 In 1968, NDGA was 
shown to induce cystic nephrotoxicity by the Canadian Food and Drug Directorate.
51
 Due to this 
finding, the use of NDGA as a food preservative was banned in Canada. Subsequently the U.S. 
Food and Drug Administration removed NDGA from its “Generally Recognized As Safe” 
(GRAS) list in 1970.
37,41,51
 There is also evidence that NDGA acts as a pro-oxidant in rat 
hepatocyte cultures at higher concentrations leading to oxidative stress, oxidative cell injury and 
cytotoxicity.
48
 Contrarily, at lower concentrations NDGA has displayed beneficial antioxidant 
effects.
48
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2.6 Drug-Drug Interactions 
Polypharmacy, the use of multiple medications, is common in North America especially among 
the elderly (65+), of which, over 50% take five or more prescription drugs at one time.
52,53
 Drug 
interactions occur when a drug, pollutant or dietary constituent alters the pharmacokinetic or 
pharmacodynamic properties of a co-administered drug.
3
 The effects can be antagonistic, 
additive, synergistic or idiosyncratic and can result in treatment failure, increased 
pharmacological effects or toxicity.
3
 Pharmacodynamic interactions occur when the effects of a 
drug are either exaggerated or diminished without affecting its disposition or metabolism.
3,52
 
Pharmacokinetic interactions occur when one drug affects one or several of absorption, 
distribution, metabolism, and elimination (ADME) processes of another drug. This often occurs 
because one drug inhibits or induces the metabolism of the co-administered drug.
3
 The effects of 
a drug, desirable or undesirable, are related to its concentration at its site(s) of action.
4
  
 
Drug interactions may occur based on a combination of mechanisms.
4,54,55
 For example a drug 
could both induce and inhibit an enzyme, or it could inhibit an enzyme and a transporter.
4
 The 
prediction of in vivo interactions based on extrapolation from in vitro results is exceedingly 
challenging when there are multiple factors that affect clearance and multiple mechanisms of 
interaction.
4,56,57
  
 
2.6.1 Enzyme inhibition and induction 
Enzyme induction is the increased activity of an enzyme after exposure to an environmental 
factor, i.e. drug, toxicant or dietary constituent. If the environmental factor is no longer present, 
the activity of the enzyme will slowly return to baseline levels.
58
 Increased metabolic activity can 
occur through a variety of mechanisms such as: increasing the amount of enzyme produced, 
stabilizing the enzyme, which allows for more efficient catalysis or by preventing the 
degradation of the enzyme. Enzyme inhibition is the reduction of enzyme activity after exposure 
to an environmental factor.
57
 Inhibition can occur through many different mechanisms, 
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including: decreased enzyme production, inhibition of catalytic activity and increased 
degradation.
58
 This is an important problem in the pharmaceutical and health sectors. While 
many drug-drug interactions have been identified and reported to health-care practitioners and 
patients, this has not been the case for most drug-natural product interactions. Since many natural 
products are self-medicated, the potential for serious drug-natural product interactions is a 
concern.
59
  
 
2.6.2 Drug-drug interaction warning labels  
Information on a drug-drug interaction could lead to a decision to alter the dose or dosage 
regimen or avoidance of the drug-drug interaction altogether.
4
 However, warnings on drug labels 
may have limited effectiveness as there are numerous examples, such as astemizole, requiring 
withdrawal from the market because warning labels did not adequately manage the risk of drug 
interactions.
60
  
 
2.6.3 Metabolism-based drug-drug interactions 
Many different metabolic routes of elimination can be affected by concomitant drug treatment.
4
 
Metabolic drug-drug interactions can cause changes on the scale of an order of magnitude or 
more in blood and tissue concentrations of a drug or metabolite. This can in turn affect the extent 
to which toxic or active metabolites are formed. Large changes in drug or active metabolite 
exposure can alter its safety and efficacy profile. Changes in exposure are always a concern but 
are especially significant when a drug has a narrow therapeutic range.
4
  
 
Drug-drug interactions can differ among individuals based on genetic variation of a polymorphic 
enzyme.
4
 An example of a human polymorphic metabolic enzyme is CYP2D6, a drug 
metabolizing enzyme. An individual who has an enzyme phenotype that is less active than the 
general population, or the most common phenotype, is considered a poor metabolizer of 
CYP2D6. Conversely an individual with a phenotype that is more active than average is 
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considered an extensive metabolizer. It is important to study the effect of drug-drug interactions 
in people with different and varied genotypes or phenotypes.
4
 
 
2.6.4 Transporter-based drug-drug interactions 
Transporters govern the transport of solutes, including drugs and other xenobiotics, into and out 
of cells.
4
 Transporters are present in all body tissues and play important roles in drug 
distribution, tissue-specific drug targeting, drug absorption, and elimination.
4,54,57
 Most identified 
transporters belong to either the ATP-Binding Cassette (ABC) superfamily or the Solute Carrier 
(SLC) superfamily.
4
 
 
The pharmacokinetics of a drug may be altered if a co-administered drug is an inhibitor or an 
inducer of its transporter.
4,54
 Various drugs (e.g. verapamil) have been documented as increasing 
plasma levels of digoxin by inhibiting the efflux transporter, P-gylocoprotein (P-gp), at the 
intestinal level.
54
 The schisandrins, which are present in a number of traditional Chinese 
medicines,  are also known to inhibit P-gp, so caution must be exercised in their use with narrow 
range therapeutics like digoxin.
61
 It should be noted that drug-drug interactions can have 
beneficial effects as well. Cidofovir, an antiviral drug, causes nephrotoxicity, while probenecid 
inhibits organic anion transport in the kidney. If cidofovir and probenecid are co-administered, 
prebenecid prevents the uptake of cidofovir into the kidney reducing toxicity.
4
  
 
2.7 Adverse Reactions 
Adverse reactions are defined by Health Canada as undesirable effects of health products.
60
 
Drugs (prescription and non-prescription pharmaceuticals, vaccines etc.), medical devices and 
natural health products fall under the umbrella of health products. In Canada, the Food and Drug 
Act and the Food and Drug Regulations, regulate health products after they are approved for use. 
The Food and Drug Regulations define an adverse drug reaction as a “noxious and unintended 
response to a drug which occurs at doses normally used or tested for the diagnosis, treatment or 
prevention of a disease or the modification of an organic function”.60 Reactions may occur 
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almost immediately, within minutes, or may not be evident until years after exposure.
60
 The 
severity of reactions can range from minor (skin rash) to life threatening (heart attack).  
 
2.7.1 Monitoring of adverse reactions 
Most of the monitoring of adverse reactions after a product is marketed is done through 
voluntary reporting by both health officials and consumers.
60
 Clinical trials testing the safety and 
efficacy of a pharmaceutical drug are performed prior to releasing a product to market. 
Unfortunately, most initial clinical trials only detect adverse reactions that occur commonly or 
frequently among the population. Adverse reactions, which typically take a longer timeframe to 
develop, are less likely to be observed in the number of patients involved in a clinical trial. In 
addition, the controlled setting and exclusion criteria of a clinical trial may not be reflective of 
the drug’s use once marketed. Voluntary reports of adverse reaction may illuminate previously 
unknown adverse reactions.
60
 Health Canada estimates that 41% of adverse reactions due to 
NHPs are reported
19
 but this is unusually high compared to other voluntary reporting systems. 
The literature has established significant under reporting of adverse reactions in voluntary 
reporting systems for pharmaceutical products with only about 5% of incidences reported.
21-24
 
 
2.7.2 Idiosyncratic drug reactions 
Idiosyncratic drug reactions (IDRs) are considered a subclass of adverse reactions that do not 
occur in most patients and do not involve the therapeutic effect of the drug.
62
 IDRs are 
unpredictable and often life threatening. There is evidence to suggest that most IDRs are immune 
mediated and caused by reactive chemical species. This means that even if a dug has the 
chemical characteristics to cause an IDR it is the patient-specific factors that determine 
susceptibility. IDRs represent a major problem for drug development and a large area of 
uncertainty for pharmaceutical companies because IDRs are not normally detected during 
clinical trials. Serious IDRs have led to the withdrawal of drugs from the market. The 
unpredictable nature of IDRs and the multiple mechanisms by which they can occur make 
developing mechanistic studies in humans difficult, and there are presently few valid animal 
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models.
62
 Processes that are believed to contribute to IDRs (reactive intermediates, free radical 
formation, reactive oxygen species and oxidative stress) are outlined in the following sections. It 
should be noted that these processes can also have direct toxicological consequences.  
 
2.7.3 Reactive intermediates 
The toxicity of many chemicals is linked to their metabolism, a concept discovered in the 
1950s
58,63
 well before many of the underlying metabolic systems were understood. Metabolism 
can lead to the formation of reactive intermediates, which can cause toxicity by covalently 
modifying biochemically important macromolecules such as proteins and deoxyribonucleic acid 
(DNA) or through inhibition of detoxification pathways. These adverse reactions are deemed 
bioactivation reactions (also called metabolic activation).
64
 Chemically, a reactive intermediate is 
a short-lived, high-energy, highly reactive molecule. Reactive intermediates are generally 
electrophiles such as quinones, epoxides, carbonium ions, and nitrenium ions.
63
 Reactive 
intermediates play an important role as toxicity mediators, therefore, it is important to consider 
the structural features and metabolic processes that lead to biological activity.
65
  
 
2.7.4 Free radicals 
Free radicals are a type of reactive intermediate that may result from bioactivation. There are 
many different sources of free radicals including: pollutants, drugs, metal ions, radiation, the 
consumption of high levels of polyunsaturated fatty acids, mitochondrial dysfunction and 
smoking.
5
 Uncontrolled free radical formation may contribute to a number of deleterious 
biological conditions including: cancer, diabetes, premature aging, and neurological, lung, 
vascular, autoimmune, and ocular diseases.
5
  
 
2.7.5 Reactive oxygen species 
Reactive oxygen species (ROS) is a term encompassing numerous compounds such as singlet 
oxygen, superoxide, peroxide, nitric oxide, peroxynitrite, peroxyl radical and hydroxyl radical 
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which can be formed through a variety of processes including metabolic bioactivation.
64
 ROS 
can cause cellular damage directly by oxidizing or reducing cellular macromolecules. The cell 
damage that occurs as a result of ROS is called oxidative stress. ROS can oxidize DNA leading 
to mutations, oxidize proteins and oxidize lipids to form lipid peroxides. Lipid peroxides are 
thought to play an important role in the promotion and progression stages of chemical 
carcinogenesis. Lipid peroxidation generates a complex array of reactive electrophilic products 
and free radicals that react with proteins and DNA.
66
 ROS can also cause damage indirectly by 
generating more ROS through propagation reactions.
64
  
 
2.7.6 Oxidative stress 
Oxidative stress is a term used to describe an imbalance between oxidants (ROS) and 
antioxidants in a system.
64,67
 Oxidative stress may result from the overproduction of ROS and/or 
a decreased ability to deactivate them. Antioxidants are defined as “any substance that, when 
present at low concentrations compared with that of an oxidizable substrate, significantly delays 
or inhibits oxidation of that substrate”.67 This definition includes both enzymes and non-
enzymatic substances. An increasing number of chemicals, have been shown to function as 
antioxidants including glutathione, vitamin C, vitamin A, and vitamin E
64,67
. These compounds 
work by intercepting the ROS and reacting with them to form non-reactive end products in a 
process known as deactivation.
67
  
 
2.8 Xenobiotics  
Xenobiotics are compounds that are foreign to a living organism, in this case, humans.
64
 
Xenobiotics are immensely diverse in size and shape, which is not surprising given the many 
sources of compounds, both natural (including natural health products) and anthropogenic that 
the human body is exposed to.
58
 As foreign compounds, xenobiotics are recognized by the 
organism to be potentially detrimental to its survival; therefore, the organism takes steps to 
protect itself.
64
 The first line of defense for humans consists of a number of transporter systems, 
such as P-glycoprotein, in the gastrointestinal tract that prevents xenobiotic absorption by 
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facilitating efflux from the enterocytes into the lumen.
64
 If a xenobiotic is absorbed, it must be 
eliminated through excretion. In humans, excretion of most xenobiotics occurs through the bile 
and urine.
64
 If a xenobiotic is lipophilic it is likely able to diffuse through lipid membranes, 
making it difficult to excrete. Metabolism of xenobiotics has evolved to primarily serve two 
functions: (i) to convert xenobiotics to more polar, hydrophilic entities that are more readily 
excreted and (ii) to attenuate any pharmacological activity.
58,64,68
  
 
2.9 Xenobiotic Metabolism 
A number of xenobiotic metabolism pathways have been identified. The enzymes identified in 
these pathways are often enzymes responsible for the metabolism of endogenous compounds. 
Xenobiotic metabolism typically occurs in the liver, though other tissues, such as the 
gastrointestinal tract, lung and kidney, may also contribute to xenobiotic metabolism.  
 
Richard Tecwyn Williams, defined Phase I metabolism as oxidation, reduction and hydrolysis 
reactions or functionalization processes. Phase I metabolism is primarily catalyzed by 
cytochrome P450-dependant mixed-functional oxidases.
68
 Phase II metabolism is comprised of 
conjugation reactions for example glucronidation and sulfonation which add a glucuronic acid of 
sulfonate group to a nucleophilic O or N-atom in a drug via the action of uridine diphosphate 
glucuronosyltransferase or sulfotransferase. Phase II metabolism normally results in water-
soluble metabolites that are readily excreted.
69
 Later Phase III metabolism was added to this 
classification system and encompasses antiporter activity, enzymes that transport drugs out of a 
cell, like the multidrug resistance-associated protein (MRP).
68,69
  
 
All enzyme systems discussed are subject to great variability in their capacity to metabolize 
various xenobiotics.
58
 Factors including gender, sex, age, disease, diet, exposure to 
environmental chemicals and genetic polymorphisms all contribute to population variability.
58
 
This is one of the reasons only a fraction of the population will encounter adverse reactions to a 
drug or experience increased toxicity. 
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2.9.2 Phase I metabolism 
Phase I metabolism reactions are characterized by the addition or exposure of a polar functional 
group. Phase I reactions generally consist of oxidation, hydroxylation, reduction and hydrolysis 
reactions. There are many different classes of phase I enzymes including: Cytochrome P450s 
(P450), flavin containing monooxygenases (FMOs), alcohol dehydrogenase (AD), aldo- and 
keto-reductases, aldehyde and xanthine oxidases, peroxidases, amine oxidases and epoxide 
hydrase.  
 
2.9.2.1 Cytochrome P450  
Cytochrome P450 enzymes are a ubiquitous system of heme-thiolate enzymes encountered in all 
domains in life. They were discovered in 1964 and probably evolved concomitantly with green 
plants started to liberate O2 into the atmosphere.
58,64
 Cytochromes are proteins that contain a 
heme group and are membrane bound. All P450 enzymes have a cysteine residue located just 
prior to the N-terminus of the proximal (L) helix, which is absolutely conserved. This cysteine 
residue provides a thiolate functional group, which is ligated to the iron of the heme group, 
without this thiolate the enzyme is inactive.
58
 P450 enzymes are monooxygenase enzymes; they 
insert one atom of oxygen, from O2, into the substrate creating a hydroxyl (-OH) group while the 
other atom of oxygen is reduced to water.
58,64
  
 
2.9.2.1.1 Mitochondrial and microsomal cytochrome P450s 
There are two classes of P450 enzymes found in humans: microsomal and mitochondrial.
64
 
Mitochondrial P450 enzymes are located on the inner membrane of the mitochondria and are not 
implicated in the metabolism of xenobiotics. They are extremely important in the biosynthesis of 
endogenous compounds such as sterols.
58
 Microsomal P450 enzymes (EC 1.14.14.1) are located 
on the smooth endoplasmic reticulum.
70
 They use cytochrome P450 reductases (EC 1.6.2.4.) and 
cytochrome b5 reductase (EC 1.6.2.2) to transfer electrons from NADPH. Microsomal P450 
enzymes metabolize xenobiotics and are found at highest concentrations in the liver but are also 
found in other organs that must cope with exposure to foreign compounds such as the skin, 
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kidney, lung and gut.
58
 If cells are homogenized the smooth endoplasmic reticulum forms small 
vesicles known as microsomes.
70
 The microsomes can be collected as a pellet and used as an in 
vitro metabolic system.
70
 Microsomes that are made from liver cells contain high levels of 
xenobiotic metabolizing enzymes and are a valuable tool for studying metabolism and drug 
interactions.
71
 
 
2.9.2.1.2 Classification of cytochrome P450s 
Humans encode approximately 66 functional P450 proteins and 30 pseudo genes. P450 proteins 
are found in almost every human organ.
58
 The cytochrome P450 superfamily is first divided into 
families, which are, in turn, divided into subfamilies. Each subfamily consists of one or more 
enzyme isoforms.
58,64
 Individual P450 enzymes cannot be properly considered isoenzymes (or 
isozymes) as isozymes are different enzymes that catalyze the same reaction. For the most part 
individual P450s catalyze different reactions, though there is some overlapping specificities, so 
the term isoform was coined.
58
 P450 enzymes that belong to the same family share at least a 40% 
structural homology. Enzymes that belong to the same sub family contain at least 55 % structural 
homology.
58,64
 P450 enzymes are all denoted CYP and then identified as 
family/subfamily/protein. For instance the notation for the cytochrome P450 enzyme that 
belongs to family 3, subfamily A, protein 4 is: CYP3A4. Arabic numerators 1-50 are used for 
animal P450 families, 50-65 for fungal families, 70-100 for plant families and 100 and above are 
used for bacterial families.
58
 Differing alleles of an isozyme are indicated with a star (*) follow 
by a number, for instance CYP2D6*4.
72
 
 
2.9.2.1.3 Cytochrome P450 metabolism 
Families CYP1, CYP2, CYP3 and CYP4 perform xenobiotic metabolism, although CYP4 is 
minimally involved. The majority (90%) of xenobiotic oxidations are catalyzed by CYP1, CYP2 
and CYP3.
64
 Other cytochrome P450 families mainly metabolize endogenous substrates. 
Isoforms CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 are 
responsible for most of the xenobiotic metabolism in humans.
73,74
 Out of all the human P450s, 
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CYP3A4 has the highest level of expression, totaling 34% of all hepatic P450.
58
 It is believed 
that up to half of all xenobiotics are metabolized at least in part by CYP3A4.
58
 The CYP2 family 
displays clinically relevant polymorphisms more frequently than any other P450 family.
75
 
CYP2D6, 2C19, and 2C9 polymorphisms account for the most frequent variations in phase I 
metabolism of drugs. For example, a patient taking the anticoagulant warfarin who is 
homozygous for the CYP2C9*3 allele, would have warfarin metabolism reduced by 90%.
76
 This 
is clinically relevant as warfarin has a narrow therapeutic index. Drug-drug interactions can also 
differ among individuals based on genetic variation of a polymorphic enzyme.
4
  
 
2.9.2.1.4 Cytochrome P450 metabolism and bioactivation 
Cytochrome P450 metabolism can also contribute to the bioactivation of xenobiotics. 
Electrophiles, reactive oxygen species and radicals can all be formed as a result of P450 
metabolism.
58,64
 These are all reactive species that can cause cellular damage leading to cell 
death or cancer. Any factor that influences the metabolism of these chemicals will also affect 
their toxicity.
64
  
 
2.9.2.1.5 Cytochrome P450 induction and inhibition 
Cytochrome P450s can be induced by their own target or by a different environmental factor.
58
 
The amount of a given P450 enzyme can be increased by up to two orders of magnitude, though 
the total amount of P450 present generally only increases two or three fold, in the presence of a 
xenobiotic. P450 may also be upregulated prior to exposure to the xenobiotic due to previous 
exposure to an environmental factor or in response to disease. This can cause a significant 
increase of enzyme activity that can lead to a build up of toxic metabolites. Conversely P450 
enzymes can be inhibited either reversibly or irreversibly by xenobiotics. If the P450 metabolism 
pathway is a deactivation pathway, inhibition can lead to increased metabolism via alternate 
routes. If those alternate pathways are bioactivation pathways this can lead to increased toxicity. 
Inhibition of P450s can also cause an increase in the concentration of a concomitant drug that is 
also metabolized by that enzyme. Overdose toxicity is particularly worrisome as the 
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consequences of such an occurrence can be fatal.
58
  
 
2.9.3 Phase II metabolism 
Phase II metabolism involves the conjugation of small polar molecules to xenobiotics or other 
environmental factors, typically resulting in water-soluble metabolites that are readily excreted.
68
 
Phase II metabolism is regarded as the detoxification step in the three phase metabolic system of 
classification,
68,69
 but it can also be a critical step for the formation of genotoxic electrophiles.
69
 
The major reactions included in phase II metabolism are glutathione conjugation, glucuronic acid 
conjugation, N-acetylation and sulfonation.
58,68
  
 
2.9.3.1 Glutathione conjugation 
Glutathione (GSH) is the common name for the tri-peptide -L-glutamyl-L-cysteinyl-glycine58 as 
shown in Figure 2.9.  
 
 
Figure 2.9 Structure of glutathione 
GSH is the most common thiol-molecule in all mammalian cells; its concentration in human 
hepatocyte cytosol is approximately 10 mM.
58
 GSH participates in many biochemical processes 
including maintenance of redox homeostasis and the trapping of electrophiles. GSH is a 
scavenger molecule that can spontaneously react non-enzymatically with electrophilic and 
radical species, i.e. quinones and semiquinone radicals. The sulfur atom of the GSH is a “soft” 
nucleophile (one with easily polarizable electrons) and reacts preferentially with soft 
electrophiles.
58
 GSH is important in protecting the cell against ROS and oxidative stress. 
 
COOH
NH
NH COOHNH2
O
O
SH
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After conjugation of substrate (X) to GSH, the resulting adduct is denoted X-SG as the GSH is 
always bonded to the substrate at the sulfur atom of the cysteine residue. Though GSH 
conjugation is normally a detoxification function there are a few instances where conjugation 
increases toxicity. One example of this is the xenobiotic dichloromethane; its reaction with GSH 
yields formaldehyde via the intermediate S-chloromethyl-SG. Both the GSH adduct and 
formaldehyde are more toxic than dichloromethane. The most common case of toxicity 
associated with this metabolism pathway is not the formation of reactive metabolites, but the 
depletion of GSH from the cell. This leaves the cell vulnerable to damage from electrophiles and 
ROS that GSH normally scavenges, it can also cause metabolism to proceed down an alternate, 
possibly more toxic pathway.
58
  
 
2.10 Quinones 
Quinones are a class of cyclic organic compounds containing two carbonyl groups (Figure 2.10). 
If the carbonyl groups are adjacent to each other, they are in the ortho- configuration and called 
an ortho-quinone (o-Q). If a vinyl group separates the carbonyl groups, they are in a para 
configuration (p-Q).  
 
 
Figure 2.10 Basic structure of an ortho-quinone (left) and a para-quinone (right). 
Quinones and their phenolic precursors (Figure 2.11) are naturally occurring compounds that are 
ubiquitous in nature.
15
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Figure 2.11 Basic structure of the phenolic precursors of an ortho-quinone (left) and a para-
quinone (right). 
Humans are exposed to quinones through the consumption of fat, pharmaceutical drugs, natural 
health products and environmental pollutants such as polycyclic aromatic hydrocarbons.
15,77
 
Quinones are involved in a vast array of biological and chemical processes, including: the 
electron transport chain (ETC) in animals and plants, photosynthesis, post-translational 
modification of proteins and metabolism of cellular signaling molecules.
77
  
 
2.10.1 Quinone toxicity  
Quinones can have various toxicological effects in vivo, including cytotoxicity, immunotoxicity, 
and carcinogenesis.
14
 Quinones are highly reactive compounds as they are both oxidants and 
electrophiles.
15
 Covalent bonding can cause cytotoxicity if the electrophilic quinones react with 
nucleophilic groups on cellular macromolecules, like thiol and amine groups in proteins and 
DNA, forming reversible or irreversible adducts. Irreversible covalent bonding can cause 
structural or functional changes of cellular macromolecules resulting in cytotoxicity.
14,16
  
 
Quinones are also potent redox active compounds, which can undergo redox cycling with their 
semi-quinone radicals, generating reactive oxygen species (ROS) and leading to oxidative stress 
through the formation of oxidized cellular macromolecules, including: lipids, proteins and DNA 
(Figure 2.12).
14,16
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Figure 2.12 Redox cycling of an ortho-quinone with its semiquinone radical leads to the 
formation of reactive oxygen species causing the oxidation of cellular macromolecules 
leading to oxidative stress. The ortho-quinone may also covalently bind to cellular 
nucleophiles to form adducts 
 
2.10.2 Quinone methides 
Quinone methides (QMs) differ structurally from quinones, as one carbonyl group is replaced by 
a methylene or substituted methylene group.
78
 Figure 2.13 shows an example of a para-quinone 
methide (p-QM). QMs have been implicated in the toxicity of certain exogenous compounds 
including food additives such as butylated hydroxytoluene (BHT).
79
  
 
    
Figure 2.13 General structure of an ortho-quinone (left) and para-quinone methide (right) 
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Unlike o-Qs, p-QMs are not implicated in redox cycling processes, instead they are more 
electrophilic and typically form stable adducts.
14
 
2.11 Perspective 
Lignans are found in most fiber rich plants and present enormous structural diversity. Interest in 
lignans and their use as a natural product, arose from their potential health benefits including: 
changes in blood lipid profiles, antioxidative effects and estrogenic, antiviral, antiestrogenic and 
anticarcinogenic activities.
6,8-12
 However some lignans such as NDGA also present toxicity 
concerns. To my knowledge there has been no overall structure activity relationship proposed to 
describe the potential toxicity of lignans in relation to specific structural features. SECO and 
NDGA are interesting for the purposes of investigating the structure activity relationship of 
lignans as both have potential pharmacological applications and both are oxidized to reactive 
intermediates but NDGA is associated with toxicity and SECO is not.  
 
In the drug discovery process, chemical modification is commonly used and is an accepted 
method to investigate the toxicity and/or pharmacological effects of the constituents of potential 
drug candidates. The structural features of lignans govern their metabolic pathways and likely 
have toxicological and pharmacological implications but are poorly understood. The structural 
features that alter metabolic pathways and allow the formation of reactive intermediates, 
particularly quinone formation and intramolecular cyclization processes, are of interest. 
Previously in our lab NDGA analogues were investigated for their stability in aqueous solution, 
their propensity to form quinone species and the functional groups required for intramolecular 
cyclization. This research will investigate the effect of the addition of the hydroxyl groups to the 
two-methyl groups at the γ position on oxidative metabolism of the previous NDGA analogues. 
These hydroxyl groups are indicated in Figure 2.14.  
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Figure 2.14 Structures of NDGA (left) and SECO (right) with the hydroxyl groups at the γ 
position in question circled in red. 
2.12 Purpose 
2.12.1 Rational  
Understanding the structural features that guide the mechanistic pathways to toxicity through 
oxidative metabolism is important for the overall understanding of the structure activity 
relationship influencing lignan stability and metabolism. To this end several analogues of SECO 
(SECO-1,2,3,4; Figure 2.15) with altered functional groups were previously synthesized and will 
be used to investigate substituent effects on: lignan metabolism and formation of reactive 
quinones and to probe the effect of structure on the pharmacological and toxicological properties 
of SECO. 
 
Figure 2.15 Structures of SECO analogues: SECO-1 (1), SECO-2 (2), SECO-3 (3), SECO-4 
(4) 
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These specific analogues were chosen to build on previous research with NDGA analogues 
(Figure 2.16) with SECO-1 corresponding to NDGA-1.  
 
Figure 2.16 Structures of NDGA analogues: NDGA-1 (1), NGDA-2, (2), NDGA-3 (3), 
NDGA-4 (4) 
SECO analogues 1, 2 and 4 were synthetic intermediates isolated during the preparation of the 
NDGA analogues;
38
 SECO-3 was prepared as a direct SECO analogue to NDGA (i.e. a di-
catechol lignan). The goals of the NDGA study were to determine the structural features required 
for dibenzocyclooctadiene formation and how substituents influenced stability. The presence of 
the -OH groups in the SECO analogues introduces the ability for these lignans to be involved in 
unique intramolecular cyclization reactions, such as that observed for SECO to lariciresinol 
conversion (see Figure 2.6). As lignans continue to be investigated for their pharmacological 
properties, an understanding of the influence of the -OH groups on lignan stability and 
metabolism is a crucial component for further development of lignans as potential therapeutic 
agents.  
Autoxidation studies will be performed to determine the stability of each analogue. Enzymatic 
oxidation experiments will be completed to determine which structural features influence 
quinone formation.  The purpose of this research is to probe the effect of structure on the 
pharmacological and toxicological properties of lignans. 
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2.12.2 Hypotheses and Objectives 
2.12.2.1 Hypothesis 1 
All SECO analogues will form quinones. Catechol analogues will form ortho-quinones. Phenol 
analogues will form para-quinone methides  
2.12.2.1.1 Objectives 1  
1. Determine the rate of autoxidation of the SECO analogues.  
2. Determine the in vitro hepatic oxidative metabolism and bioactivation of the SECO 
analogues. 
2.12.2.1.1.1 Specific Aims 1 
1. Develop a high performance liquid chromatography (HPLC) method for the detection 
and separation of SECO analogues and autoxidation products.  
2. Quantify the stability of the SECO analogues in buffer at pH 6.0 and pH 7.4  
3. Identify the autoxidation products using mass spectrometry (MS)  
2.12.2.1.1.2 Specific Aims 2 
1. Develop an HPLC method for the detection and separation of metabolites.  
2. Perform enzymatic and chemical oxidation experiments on the SECO analogues using 
glutathione as a trapping agent  
3. Perform microsomal incubation experiments on the SECO analogues using glutathione as 
a trapping agent. 
4. Identify glutathione adducts and lariciresinol-like metabolites using MS  
2.12.2.2 Hypothesis 2 
All SECO analogues will inhibit cytochrome P450 isoforms CYP3A4, CYP3A5, CYP2C9 and 
CYP2C19. 
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2.12.2.2.1 Objectives 2 
1. Determine the ability of the SECO analogues to inhibit cytochrome P450 isoforms 
CYP3A4, CYP3A5, CYP2C9 and CYP2C19. 
2.12.2.2.2.1.1 Specific Aims 1 
1. Determine the in vitro IC50 inhibition values for all of the SECO analogues and SECO 
against the cytochrome P450 isoforms CYP3A4, CYP3A5, CYP2C9 and CYP2C19. The 
inhibition study will be carried out by Life Technologies. 
 
3.0 Materials and Methods 
3.1 Materials  
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): AgNO3, 
dimethyl sulfoxide (DMSO), ethylenediamine-tetracetic acid (EDTA), eugenol, reduced 
glutathione (GSH), KCl, MgCl2, mushroom tyrosinase, NaOH, reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) tetrasodium salt, protease inhibitor cocktail (P8215), 
salicylamide, sodium pyrophosphate (Na4O7P2) and sucrose. Formic acid, KOH, Na2HPO4, and 
perchloric acid were obtained from BDH Chemicals (Toronto, ON). Rat Liver Microsomes 
(0.5mL; 20mg/mL; Lot# RT053C) were purchased from Invitrogen (Life Technologies; 
Burlington, ON). Dithiolthreitol (DTT), and Pierce® BCA Protein Assay Kit were obtained from 
Thermo Scientific (Milwaukie, WI). Tris hydrochloride was obtained from EMD Millipore 
(Billerica, MA). Acetonitrile, ethyl acetate, glycerol, HCl, and methanol were obtained from 
Fisher Scientific (Fairlawn, NJ); C2D3N (acetonitrile-d3) was obtained from Cambridge Isotope 
Laboratories Inc. (Andover, MA). Silver oxide (Ag2O) was freshly prepared from AgNO3 and 
KOH according to a literature procedure.
80
 HPLC runs were performed with HPLC grade 
acetonitrile from Fisher Scientific (Fairlawn, NJ) and water was filtered using a Millipore, Milli-
Q system with a Quantum EX cartridge (Mississauga, ON). LC/MS grade water (Milli-Q H2O), 
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methanol and acetonitrile were used for all LC-MS analyses and obtained from Fisher Scientific 
(Fairlawn, NJ). 
 
3.2 High Performance Liquid Chromatography (HPLC)  
HPLC was performed on a Waters Alliance 2695 Separations Module (Milford, MA) using a 
Waters 2996 Photodiode Array Detector ( = 280; Milford, MA) and Empower software (2002; 
Build Number 1154). An Agilent Poroshell 120 EC-C18 4.6 × 50 mm 2.7 μm column 
(Mississauga, ON) with an injection volume of 10 L at room temperature was used for 
compound separation. A linear gradient mobile phase system, solvent A was water with 0.1% 
formic acid and solvent B was acetonitrile with 0.1% formic acid. Both solvents were filtered 
through a 0.45 micron filter, sonicated and degassed prior to use. The HPLC gradient outlined in 
Table 3.1 was used to detect and separate compounds. 
 
Table 3.1 HPLC gradient program employed for the separation of SECO analogues and 
metabolites 
Time (min) Flow rate (mL/min) % Solvent A
1
 % Solvent B
2
 
0 0.5 85 15 
17 0.5 85 15 
27 0.5 30 70 
30 0.5 10 90 
35 0.5 10 90 
36 0.5 85 15 
39 0.5 85 15 
40 0 85 15 
1 
water with 0.1% formic acid 
2 
acetonitrile with 0.1% formic acid 
3.3 SECO Analogue Stability at pH 6.0 and 7.4 
A 1 mM solution of each SECO analogue was prepared in a Na2HPO4 (50 mM) buffer of the 
desired pH (6.0 or 7.4). Each sample was vortexed for 5 s and placed in a water-bath heated to 37 
°C and shaken at 150 rpm. A pseudo time 0 sample was taken after 15 s on the shaker by 
removing a 500 μL aliquot and quenched with 20 μL perchloric acid for a final pH ~2 to stop the 
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reaction. For analysis an internal standard (KA-1-09-2; Figure 3.1) was added and samples were 
analyzed using the HPLC method described above.
11
 The solution was returned to the incubator 
and samples were taken at 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 10 h, 12 h, 24 h and 
48 h time points.  
 
Figure 3.1 Structure of KA-1-09-2 used as the internal standard 
3.4 Determination of decomposition products 
The major decomposition product of SECO-3 was the only decomposition product present in 
sufficient quantity that NMR analysis was possible. SECO-3 (1 mM; 5 mg total) was allowed to 
decompose in Na2HPO4 buffer (50 mM; pH 7.4) at 37ºC. The reaction was halted at 8 h with the 
addition of perchloric acid (200 μL). The pH was checked to ensure that it was less than pH 2. 
Factions were collected using an Agilent 1200 LC (Santa Clara, CA) and fraction collection 
based on deviation from baseline. The product fraction was concentrated by using a Buchi R-200 
rotary-evaporator with a V-850 Vacuum controller (New Castle, DE) to drive off the acetonitrile. 
It was then flash frozen using liquid nitrogen and lyophilized using a Labconco Freezone 6 Plus 
lyophilizer (Kansas City, MO) for more than 24 h. Approximately 1 mg of product was obtained. 
The product was then analyzed by 
1
H nuclear magnetic resonance (NMR) spectroscopy on a 
Bruker AVANCE DPX-500 spectrometer (Rheinstetten, Germany) and data processed by X-
WIN NMR 3.5 software or TopSpin 3.2. 
 
3.5 Silver Oxide Preparation 
The procedure employed was based on that outlined in Yu et al., 2004.
80
 KOH (0.72 g) was 
added to 20 mL Milli-Q H2 and allowed to dissolve completely at room temperature. AgNO3 (2.0 
g) was added to 20 mL milli-Q H2O and stirred for 10 min. The KOH solution was combined 
OH
OH OCH 3
H3CO
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with the AgNO3 solution and stirred for a further 15 min. A black precipitate of Ag2O forms 
following the reaction: 
2KOH + 2AgNO3  Ag2O + 2KNO3 + H2O 
 
The precipitate was filtered and washed with H2O (3 x 10 mL).  Ag2O is light sensitive so it was 
covered and dried on a high vacuum pump overnight.
80
  
 
3.6 Silver Oxide Oxidation 
This procedure is based on the method outlined in Krol and Bolton, 1997.
81
 Stock solutions of 
each SECO analogue (0.1 M; DMSO) were dissolved in 4 mL acetonitrile to a final 
concentration of 1 mM. Ag2O (0.2 g) was added and mixture was placed on a shaker (medium 
speed) for 15 min at room temperature. The reaction mixture was tremoved from the shaker and 
allowed to settle. The supernatant (1 mL) was removed and centrifuged at 14 000 rpm for 10 min 
in an Eppendorf S417C centrifuge (Mississauga, ON). An aliquot of the supernatant (250 μL) 
was added to Na2HPO4 buffer (50 mM; pH 7.4) either with or without glutathione (GSH) (50mM 
in Na2HPO4; pH 7.4; 5:1 GSH/substrate ratio) to a final volume of 5 mL. 500 μL aliquots were 
used for HPLC analysis using the previously described method. Another 500 μL aliquot was 
used for mass spectrometry (MS) analysis. UV-Vis spectrophotometry (Agilent 8453; Santa 
Clara, CA;  = 200 – 400 nm) was also performed at each stage of the experiment. This 
experiment was performed with SECO analogues 2 and 3 as well as the model compound 
eugenol.  
 
3.7 Enzymatic Oxidation using Mushroom Tyrosinase 
Oxidation of SECO and its analogues was performed at pH 6.0 utilizing mushroom tyrosinase 
(EC 1.18.14.1) isolated from the mushroom species Agaricus bisporus.
82
 Mushroom tyrosinase is 
catalytically active at pH 6.0 and this protocol is consistent with previous experiments.
82
 
Mushroom tyrosinase is an enzyme known to exhibit wide substrate specificity and readily 
oxidizes a number of o-diphenolic compounds.
78
 GSH was used as trapping system; it will 
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conjugate to metabolites, specifically quinones produced from the enzymatic oxidation and form 
GSH adducts.
83
 Glutathione S-transferase is not necessary for this reaction to occur. A 5:1 ratio 
(GSH:substrate) was used, 100 μL of GSH (50 mM) in Na2HPO4 buffer (50 mM, pH 6.0) for a 
final concentration of 5 mM. The position of the GSH in the adduct will determine if an ortho-
quinone (o-Q) or p-QM was produced.
83
 Each SECO analogue (1 mM) was prepared in 
Na2HPO4 buffer (50 mM; pH 6.0) with a final volume of 1 mL with or without GSH (5 mM). 
 
Mushroom Tyrosinase (8μL of 8.63736 U/μL stock solution) was added to the SECO analogue 
mixture and vortexed for 5 s. A 500μL aliquot was immediately removed and quenched with 
perchloric acid (20 μL) to a final pH ~ 2 to stop the reaction. This was used as time 0. The 
sample was then centrifuged at 14 000 rpm for 10 min and the supernatant was kept for analysis. 
The remainder of the reaction mixture was placed in a Boekel Grant ORS 200 water bath 
(Feasterville, PA) at 37 °C and shaken at 200 rpm for 60 min. The reaction was quenched and 
centrifuged as described for the time 0 sample. The results of this experiment were analyzed 
using HPLC as described above, MS and liquid chromatography-mass spectrometry (LC-MS). 
Experiments were run in triplicate. 
 
3.8 Sample Preparation for Direct Infusion Mass Spectrometry  
For samples containing GSH solid phase extraction was used. using a Waters Sep-Pac C18 Vac 
cartridge (Waters, Milford, MA) and an extraction manifold (Waters, Milford, MA). The 
cartridge was activated with methanol (5 mL) then washed with Milli-Q H2O (15 mL). The 
sample (500 μL) was loaded onto the column and was washed with Milli-Q H2O (5 mL) to 
remove salts. Metabolites were washed off the column with methanol (2 x 1 mL).  
 
For samples not containing GSH, liquid-liquid extraction was performed. Ethyl acetate (0.5 mL) 
was added to the sample and the mixture was inverted (10x) and allowed to settle. The ethyl 
acetate layer was retained and evaporated on a high vacuum pump overnight. The following 
morning extraction products were re-dissolved in methanol (0.5 mL). Two different methods 
were necessary due to the differences in polarity of the metabolites produced. 
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3.9 Direct Infusion Mass Spectrometry 
Mass spectrometry was performed on an AB Sciex 4000 QTRAP mass spectrometer 
(Framingham, MA) using Analyst software (version 1.6.2). ESI (-) was first used to generate 
MS
1
 full mass spectra with a range of 100 – 700 mass-to-charge ratio (m/z). If a GSH adduct was 
suspected ESI (+) was then used to perform tandem mass spectrometry (MS/MS; MS
2
) (see 
Table 3.2). We previously developed a method of differentiating aromatic and benzylic GSH 
adducts.
39
 This technique was used to perform neutral loss (NL) scans looking for a neutral loss 
of 129 or 307. Neutral loss of 129 is indicative of an aromatic GSH conjugate, while a neutral 
loss of 307 is indicative of a benzylic GSH adduct. The precursor ions that are identified by the 
neutral loss scans were then selected to undergo collision induced dissociation (CID) product ion 
scans. If the precursor ions are glutathione adducts they show characteristic fragmentation 
pathways as shown in Figure 3.2. 
 
     
Figure 3.2 Fragmentation pathway of aromatic (left) and benzylic (right) GSH conjugates 
following collision induced dissociation (CID) for SECO analogues. Developed by Isaac 
Asiamah. 
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Table 3.2. Expected m/z ESI (+) for the product ions of the GSH adduct fragmentation 
pathway pictured in Figure 3.2. P represents the parent ion. Developed by Isaac Asiamah. 
Fragment Type Positive m/z Fragment Type Positive m/z 
a P-75 g P-232 
b 145 h P-249 
c P-146 i 308 
d P-275 j P-307 
e P-129 k 274 
f 130   
 
3.10 Liquid Chromatography – Mass Spectrometry (LC-MS) 
The same liquid chromatography method described in High Performance Liquid 
Chromatography (HPLC) was used on an Agilent 1200 LC (Santa Clara, CA) with a AB Sciex 
4000 QTRAP mass spectrometer (Framingham, MA) using Analyst software (version 1.6.2). ESI 
(-) MS
1
 with a m/z range of 100 – 700 and NL (+; 129 and 307) mass spectra were collected. 
Scans were conducted every 1.5 s.  
 
3.11 Rat Liver Microsome Preparation 
The protocol for animal use (20030062) was approved by the University of Saskatchewan 
UCACS Animal REB . Liver microsomes are subcellular particles derived from the endoplasmic 
reticulum of hepatic cells.
71
 Rat liver microsomes were prepared from the pooled livers of 3 adult 
male Sprague-Dawley rats using the Krol Lab Preparation of Hepatic Microsomes – Standard 
Operating Procedure. 
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3.11.1 Preparation of stock solutions 
All stock solutions were prepared in advance and stored at 4°C until use. Milli-Q H2O was used 
to make all stock solutions.  
 
A. Homogenization Buffer (100 mL) 
50 mM Tris Buffer 
150 mM KCl,  
0.1 mM Dithiothreitol,  
1 mM  Ethylenediamine-tetracetic acid  
20% Glycerol.  
Chill to 4°C and pH to 7.4 with HCl 
 
B. Protease Inhibitor cocktail (Sigma Aldrich; P8215)  
 Store at -20°C 
 
C. Microsomal Storage Solution (100 mL) 
0.25 M Sucrose 
Note sucrose solution has a shelf life of 1 week. 
 
D. Microsomal wash solution (100 mL) 
 50 mM KCl 
 
3.11.2 Microsome preparation  
Microsome preparation was performed in a 4 °C cold room. All necessary instruments and 
solutions were brought to the cold room and chilled prior to commencement. Protease inhibitor 
cocktail (500 μL) was added to the homogenization buffer. The rat liver was chopped into larger 
pieces and 2-3 g of liver tissue was weighed out and placed in the 30 mL Wheaton Teflon tissue 
homogenizer glass sleeve (Millville, NJ). Homogenization buffer (10 mL) was added to the glass 
sleeve and the teflon tipped pestle of the tissue homogenizer (Wheaton, Millville, NJ) was used 
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to grind all of the liver into solution. The pestle was then passed through the solution 10 more 
times taking care that the homogenate remains cold. The homogenate was stored on ice until all 
of the liver tissue was homogenized. Homogenate was pooled. A Beckman Coulter Optima L-
90K ultracentrifuge (Brea, CA) and a Type 60 Ti ultracentrifuge rotor (Beckman Coultre; Brea, 
CA) were used for all the centrifugation. First a low speed centrifugation at 10,000 rpm (RCF = 
10041.8 × g) for 30 min was used to separate out the late cellular particles such as the nucleus, 
mitochondria and lipid membrane into the pellet. The supernatant was collected and centrifuged 
at 35,000 rpm (RCF = 123012.4 × g) for 30 min. to separate the smooth and rough endoplasmic 
reticulum from the cytosol. The supernatant was then removed and the pellet was washed with 
microsomal wash solution (5 mL). The pellet was again centrifuged at 35,000 rpm (RCF = 
123012.4 × g) for 30 min. The resulting pellet was reconstituted in microsomal storage buffer (2 
mL). Aliquots (500 μL) were transferred into labeled microfuge tubes and stored at -80 °C.   
 
Rat Liver Microsomes (0.5mL; 20mg/mL; Lot# RT053C) were also purchased from Invitrogen 
(Life Technologies; Burlington, ON) for method development. Protein concentration was 
determined using Pierce® BCA Protein Assay Kit 
 
3.12 Rat Liver Microsome Oxidation 
Niemeyer et al., 2003, established that SECO undergoes oxidative metabolism when incubated 
with liver microsomes (rat and human).
10
 The major product of SECO’s metabolism was 
lariciresinol though there were also at least 5 other minor products detected.
10
 Rat liver 
microsomal incubations with SECO have also been performed by Jacobs and Metzler, 1999, this 
method was modified to be consistent with previous microsomal incubations done in the Krol 
lab.
84
 This experiment was run with and without a GSH trapping system, where a 10:1 ratio 
(GSH:substrate) was utilized. The following stock solutions were prepared: 0.1M stock solutions 
of the SECO analogues in methanol or dimethyl sulfoxide (DMSO); MgCl2 (100 mM); -
nictotinamide adenine dinucleotide 2’-phosphate reduced salt hydrate (NADPH) (10 mM) in  pH 
7.4 Na2HPO4 buffer (50 mM); GSH (50 mM) in  pH 7.4 Na2HPO4 buffer (50 mM); pH 7.4 
Na2HPO4 buffer (50 mM) ; Na4O7P2 (100mM) (sodium pyrophosphate; SPP). The final volume 
of the reaction mixture was 500 L and contained: 0.5 mg/mL of microsomal protein, 0.5 mM of 
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the test compound, 5 mM MgCl2, 5 mM GSH and 10 mM SPP. This reaction mixture was pre-
incubated (5 min) in a Boekel Grant ORS 200 water bath (Feasterville, PA) at 37 °C and shaken 
at 200 rpm. The reaction was initiated with the addition of NADPH (50 L of 10 mM; 1 mM 
final concentration). The reaction was terminated after 60 min by addition of ice-cold acetonitrile 
(20 L). The sample was then centrifuged at 14 000 rpm for 10 min and the supernatant was kept 
for analysis. The results of this experiment were analyzed using HPLC, MS and LC-MS methods 
and sample preparations described above. Experiments were performed in triplicate and no 
NADPH and boiled microsomes (60 s prior to addition to the assay) were used as negative 
controls. . 
 
3.13 Cytochrome P450 Inhibition 
We contracted Life Technologies to run IC50 inhibition assays, using their SelectScreen® 
Biochemical P450 Profiling Services (Madison, WI). This screen uses P450 Baculosomes® 
containing a single human P450 isozyme and rabbit NADPH-cytochrome P450 reductase, 
prepared from insect cells with recombinant baculovirus and Vivid® Substrates. The Vivid® 
Substrates have low fluorescence until cleaved via metabolism by cytochrome P450, generating 
a highly fluorescent metabolite. Inhibitors are identified by their ability to prevent formation of a 
fluorescent signal. 
All SECO analogues and SECO were prepared at a 100X concentration (50 mM) in 100% 
DMSO and sent to Life Technologies (Madison, WI). The 100X concentration was then diluted 
to a 3X working concentration in potassium phosphate (100 mM; pH 7.4). The final well content 
of DMSO was 1%. 
 
3.14 Statistical Analysis 
GraphPad Prism 6 (La Jolla, CA) was used for statistical analysis. Linear regression analysis was 
used to determine if slopes were statistically different from zero, to determine stability and to 
determine kinetic parameters. Kinetic parameters under unstable conditions were also calculated 
using a non-linear regression fit to a phase 1 decay model. P < 0.05 was deemed significant.  
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4.0 Results 
4.1 SECO Analogue Stability 
The autoxidation of catechols is pH dependent, therefore the stability of the SECO analogues 
must be probed to determine if they have a dissociation constant at or near physiological pH.
85
 
Stability studies were performed on all SECO analogues (1 mM) at pH 6.0 and pH 7.4 in 
Na2HPO4 buffer (50 mM) at 37°C. A pilot study was conducted for 6 h, and two subsequent 8 h 
trials were run. This time frame was originally chosen as it was consistent with previous NDGA 
analogue studies. It was discovered that 8 h trials were insufficient to determine kinetic 
decomposition parameters (k and t1/2) so the duration of the trials was extended to 48 h. For 
conditions under which the analogues were deemed stable only one 48 h trial was performed to 
conserve starting material and the data from the 6 and 8 h trials was included in the statistical 
analysis. For the conditions under which analogues were deemed unstable only 48 h trial data 
was used. SECO-3 could not be detected past 10 h, no calibration curves were prepared, instead 
the relative change in peak area was followed. HPLC analysis as described in section 3.2 were 
performed monitoring decrease in starting material at  = 280. The SECO analogues that were 
unstable and decomposed, yielded multiple products. For SECO-3 the formation of a major 
decomposition product was followed. Stability experiments revealed that all SECO analogues 
were stable at pH 6.0 as no change in substrate peak areas was observed over 8h. SECO-2 was 
stable at pH 7.4, however SECO analogues 1, 3 and 4 were not stable at pH 7.4 with t½ of 9.00, 
1.73 and 7.03 h respectively (Table 4).  
 
4.1.1 Pseudo zero time-point 
During the pilot studies it was discovered that if an analogue was unstable, when the time 0 
sample was collected after vortexing but prior to being put in the water bath, the time 0 SECO 
analogue peak consistently had a smaller area than the 30 min time point (Figure 4.1). We 
attempted to solve this problem by incubating the Na2HPO4 buffer (50 mM) at 37°C for 5 min 
prior to the addition of the SECO analogues, however this did not fully resolve the problem. 
Instead, a pseudo t = 0 was collected by waiting 15 s after the sample was placed in the water 
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bath, which resolved the discrepancy. Starting material, t = 0 and pseudo t = 0 were all analyzed 
by HPLC and the mass-to-charge ratio was determined by MS. All three samples were consistent 
with the starting material. Therefore, a pseudo t = 0 point was used for all trials.  
 
Figure 4.1 1 mM SECO-1 analogue in Na2HPO4 buffer (50 mM; pH 7.4) over time (h) at 
37C. Absorbance at  = 280 nm. The peak area under the curve was normalized to the 
internal standard (KA-1-09-2). 
 
4.1.2 HPLC analysis of SECO analogue decomposition 
The following column types were tested for SECO analogue separation: C8, C18, CN, Hilic and 
NH2. The C18 column was determined to demonstrate superior resolution, retention time and 
peak shapes. Mobile phase starting conditions of 95%, 90% and 85% Milli-Q water with 0.1% 
formic acid were investigated. 85% Milli-Q water with 0.1% formic acid was decided upon due 
to solubility issues with SECO-1. This also agrees with the precedent set with previous flaxseed 
lignan experiments. Different run-times, flow rates and gradients were tested. The first runs were 
on a Nova-Pak ® C18 3.9 × 150 mm column using salicylic acid as the internal standard (Figure 
4.2). It was discovered, based on the mass-to-charge ratio determined by MS, that the SECO-3 
originally used was not the correct structure. When the correct SECO-3 analogue was used the 
retention times of SECO-3 and the internal standard were too similar (RTSECO-3 = 3.6 min and 
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RTsalicylic acid = 3.9 min) therefore the internal standard was switched to KA-1-09-2 (Figure 3.1). 
None of the data collected with the previous internal standard was used. After analysis by MS, it 
was also found that the originally used SECO-1 was not actually SECO-1 but a furan 
decomposition product. SECO-1 was re-synthesized and none of the furan data is included. 
Originally a dual wavelength HPLC detector was used to detect UV absorbance, but was 
subsequently changed to a photodiode array HPLC detector to obtain greater flexibility in data 
collection. None of the data collected with the dual wavelength detector is included in this thesis.  
 
Figure 4.2 Chromatogram of SECO-1 (RT = 16.4 min) using a Nova-Pak ® C18 3.9 × 150 
mm column and salicylic acid (RT = 3.9 min) as the internal standard (IS) at λ = 280 nm.  
Using the Nova-Pak ® C18 3.9 × 150 mm column it was difficult to detect metabolites 
particularly in the absence of GSH, especially given the impurities found in the blank from the 
column that could not be removed. The starting material disappeared but no metabolites were 
detected (Figure 4.3). Further method development was done to attempt to find the metabolites 
and to increase the retention time of SECO-3. The 40 min method described in the methods 
section is the method used for all reported data including stability studies.  
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Figure 4.3 Chromatogram of SECO-1 using Nova-Pak ® C18 3.9 × 150 mm column and 
salicylic acid (RT = 3.9 min) as the internal standard (IS) at λ = 280 nm after 1 h MT 
oxidation in Na2HPO4 buffer (50 mM; pH 6.0 ) at room temperature. SF = solvent front. 
Impurities found in blank from column indicated with red circle.  
In January 2015 an Agilent Poroshell 120 EC-C18 4.6 × 50 mm 2.7 μm column became 
available. The Poroshel column has a tighter particle size distribution which greatly improves 
chromatographic separation. The application of this column to the research project significantly 
improved the quality of the data generated and allowed for the separation of metabolites and 
increased the retention time of SECO-3 allowing for the detection of SECO-3 GSH adducts. All 
metabolism studies and LC-MS analysis, were conducted on this column. For the stability 
studies, one trial at pH 7.4 data and two trials at pH 6.0 were conducted using the Nova-Pak ® 
C18 3.9 × 150 mm column. Data from both columns was used, as there was a limited amount of 
starting material available (Table 4.1). The method developed for the Agilent Poroshell 120 EC-
C18 4.6 × 50 mm 2.7 μm column is reported in the methods (section 3.2). All SECO analogues 
presented as single peaks in HPLC chromatograms for both columns. 
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Table 4.1 Summary of retention times for SECO analogues and the internal standards 
employs chromatography method described in section3.2. 
Analogue RT (min) λ (nm) 
SECO-1a 21.1 282 
SECO-1b 23.8 282 
SECO-2a 22.5 281 
SECO-2b 24.9 281 
SECO-3a 3.6 281 
SECO-3b 5.5 281 
SECO-4a 15.1 282 
SECO-4b 22.2 282 
ISa 24.3 272 
ISb 26.6 272 
salicylic acida 3.9 280 
a = Nova-Pak ® C18 3.9 × 150 mm column 
b = Poroshell 120 EC-C18 4.6 × 50 mm 2.7 μm column 
 
Below is a representative chromatogram of SECO-3 (RT = 5.4 min) at time = 0 (Figure 4.4) and 
time = 8 h (Figure 4.5) at λ = 280 nm. Decomposition of SECO-3 generated multiple products, a 
major peak (RT = 1.7 min) is observed (Figure 4.5).  
 
Figure 4.4 Chromatogram of SECO-3 stability at pH 7.4 time point t = 0 h showing SECO-
3 and KA-1-09-2 as the internal standard (IS) at λ = 280 nm.  
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Figure 4.5 Chromatogram of SECO-3 stability at pH 7.4 time point t = 8 h showing KA-1-
09-2 as the internal standard (IS), SECO-3 and the major SECO-3 decomposition product 
at λ = 280 nm.  
The disappearance of the starting material (SECO-3) and the appearance of the major 
decomposition product was plotted in Figure 4.6. Tracking the formation of the major 
decomposition product past the eight hours shown in Figure 4.6 reveals its slow decomposition 
with 8 h as its peak concentration.   
 
 
Figure 4.6 The disappearance of the starting material and the appearance of a product for 
SECO-3 in Na2HPO4 buffer (50 mM; pH 7.4) at 37ºC. 
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Unlike SECO-3, autoxidation of SECO-1 and SECO-4 did not show evidence of a major peak. 
Representative chromatographs of SECO-4 (RT = 21.8 min) at t = 0 (Figure 4.7) and t = 24 h 
(Figure 4.8), λ = 280 nm, are shown below. After 24 h there is a decrease in starting material and 
the appearance of multiple products.  
 
Figure 4.7 Chromatogram of SECO-4 stability at pH 7.4 time point t = 0 h showing SECO-
4 and internal standard (IS) at λ = 280 nm. 
 
 
Figure 4.8 Chromatogram of SECO-4 stability at pH 7.4 time point t = 24 h showing 
SECO-4, internal standard (IS) and multiple products at λ = 280 nm. 
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4.1.3 Determination of decomposition products. 
The major decomposition product of SECO-3 was the only decomposition product present in 
sufficient quantity that NMR analysis was possible. The major decomposition product of SECO-
3 was consistent with the formation of an NDGA like, dibenzocyclooctadiene derivative (Figure 
4.9). 
1
H NMR (500 MHz, CD3CN): δ (ppm) 1.31 (2H, s), 1.44 (2H, s), 2.06 (3H, s), 2.67 (5H, 
s), 3.73 (2H, s), 3.75 (2H, s), 6.64 (2H, m), 6.72 (2H, m). 
 
 
Figure 4.9 
1
H nuclear magnetic resonance (NMR), 500 MHz on a Bruker AVANCE DPX-
500 spectrometer.  
SECO-1 and SECO-4 do not form a major dibenzocyclooctadiene like product. Both SECO-1 
and SECO-4 form multiple minor decomposition products, none of which were present in 
sufficient concentration for NMR identification. MS and LC-MS data suggests other types of 
cyclized products may be present (Figure 4.10). 
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Figure 4.10 Possible structure of a SECO-1 decomposition product 
 
4.1.4 Statistics 
GraphPad Prism 6 software was used for all statistical analysis. Duplicates from each trial were 
averaged and each trial was used as an independent replicate. Eight trials were completed to get 
four trials of usable data for both pH 6.0 and 7.4. Trials were eliminated from the pool of data for 
technical issues, for example: HPLC problems part way through the analysis and a power outage 
in the middle of one of the trials. Variability was introduced into the data due to multiple factors 
including: trials run over the course of 18 months, different batches of buffer and starting 
materials, and the use of two different HPLC columns to collect data. The peak area ratio of 
sample to internal standard was used for all statistical analyses. Two different statistical analyses 
were performed on the trial data; a linear transformation followed by a linear regression and a 
non-linear regression fit to a phase 1 decay model. The results of both analyses were comparable 
therefore the results of the linear regression are reported to compare with results from similar 
work with NDGA analogues. The results from the non-linear regression analysis are reported in 
appendix A.   
 
4.1.4.1 Linear transformation 
Integrated rate law for 1
st
 order kinetics 
ln[𝐴] =  −𝑘𝑡 + ln[𝐴]𝑜 
Solve for t1/2 
𝑡1
2
=  
ln 2
𝑘
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This calculation can be used to determine the kinetic parameters manually without using 
statistical software and is an accepted method for determining k and t½ in simple, non-enzymatic 
systems. It is also based on this law that the flowing linear transformation was chosen:  
 
y =  ln ([𝐴] [𝐴𝑜])⁄  
 
Though only the unstable data were 1
st
 order reactions, a linear transformation was necessary to 
account for some of the variability between trials for statistical analysis. 
 
At pH 6.0 one trial was run to 48 h, the rest were terminated at 6 h to conserve starting material. 
None of the SECO analogues had slopes statistically different from 0 (all P > 0.05; Figure 4.11) 
at pH 6.0. Therefore all of the analogues were considered to be stable at pH 6.0 
 
Figure 4.11 Linear regression lines for 1 mM SECO analogues: SECO-1 (A1), SECO-2 
(A2), SECO-3 (A3) and SECO-4 (A4), in 50 mM Na2HPO4 buffer, pH 6.0 at 37°C. Change 
in concentration was determine from the peak area under the curve, normalized to the 
internal standard (KA-1-09-2), a linear transformation was applied and plotted as a 
function of time (h). Error bars = ± 1 SE. 
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SECO-2 was also stable at pH 7.4, with a slope not statistically different from 0 (P > 0.05). 
SECO -1, -3 and -4 had slopes statistically different from zero (P < 0.0001, Figure 4.12) and are 
therefore not stable at pH 7.4. SECO-1, -3 and -4 all show characteristics of 1
st
 order kinetics.  
 
For SECO-2 only one replicate was done to 48 h, 3 other replicates were only run until 8 h. The 
shorter time scale required fewer time points meaning a lower starting volume was required 
translating to using less starting material, saving it for other experiments. For all other analogues 
all replicates were run 48 h. 
 
Figure 4.12 First-order regression lines for 1 mM SECO analogues: SECO-1 (A1), SECO-2 
(A2), SECO-3 (A3) and SECO-4 (A4), in 50 mM Na2HPO4 pH 7.4 at 37°C over time (h). 
Change in concentration was determined from the peak area under the curve, normalized 
to the internal standard (KA-1-09-2) and plotted as a function of time (h).  Error bars = ± 1 
SE. 
Table 4.2 shows a summary of kinetic parameters for the unstable SECO analogues at pH 7.4 
determined via linear transformation and linear regression.  
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Table 4.2 Summary of kinetic data for SECO analogue autoxidation at pH 7.4 using a 
linear transformation and linear regression analysis.  
 SECO-1 SECO-2 SECO-3 SECO-4 
k (h-1) 0.08 * 0.40 0.10 
t1/2 (h) 9.00 * 1.73 7.03 
R2 0.98 * 0.94 0.98 
* No change in starting material was observed over 48 h, therefore kinetic parameters were not 
determined 
  
4.2 Mushroom Tyrosinase Oxidation 
Mushroom tyrosinase (MT) oxidation was used to generate ortho-quinone (o-Q) standards of the 
SECO analogues. Oxidation was conducted in a 50 mM Na2HPO4 buffer, pH 6.0, at room 
temperature in the presence and absence of a GSH trapping system. Due to the structure of 
SECO-2 and the mechanism of action of MT it was predicted that SECO-2 would not be 
oxidized by mushroom tyrosinase. HPLC, MS and LC-MS analysis validated this prediction. 
SECO-1, -3 and -4 oxidation generated aromatic GSH adducts in the presence of GSH.  
 
4.2.1 GSH trapping system 
HPLC was used to generate chromatograms of the SECO analogues (Figure 4.13) and their 
metabolites (Figure 4.15). ESI (-) was used to generate MS
1
 full mass spectra with a range of 100 
– 700 mass-to-charge ratio (m/z). An ion with the m/z 606.4 was suspected to be a GSH adduct as 
it was the predicted mass. ESI (+) was then used to perform neutral loss (NL) scans looking for a 
neutral loss of 129 or 307. The NL (+) 129, indicative of an aromatic GSH conjugate, indicated a 
m/z 608.3. The precursor ion m/z 608 was selected to undergo a collision induced dissociation 
(CID) product ion scan (+) and generated the characteristic fragmentation of an aromatic GSH 
adduct. LC-MS ESI (-) MS
1
 full mass spectra with a range of 100 – 700 mass-to-charge ratio 
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(m/z) were generated from which smaller ranges of m/z were extracted to compare with HPLC 
results.  
SECO-1 data shown is representative of SECO-3 and SECO-4 pattern of oxidation. 
Chromatograms of SECO-1 from HPLC (Figure 4.13) and LC-MS (Figure 4.14) analysis.  
 
Figure 4.13 HPLC chromatogram of SECO-1,  = 280 nm. 
 
 
Figure 4.14 LC-MS ESI (-) MS
1
 scan of SECO-1, m/z 300-302 range isolated from overall 
range of m/z 100 to 700. 
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After 1 h incubation with mushroom tyrosinase in 50 mM Na2HPO4 pH 6.0 at room temperature 
with 5:1 GSH trapping system, SECO-1 shows multiple pairs of metabolites (Figure 4.15). 
 
Figure 4.15 HPLC chromatogram SECO-1 after mushroom tyrosinase oxidation with GSH 
present at  = 280 nm. The peaks at 10.4, 10.9, 18.8 and 19.8 min are consistent with GSH 
adducts due to the characteristic shift in maximum absorbance. The peaks at 24.5 and 24.9 
min are impurities present in starting material that are not metabolized. 
These identified peaks also show the characteristic shift in absorbance from the λmax = 280 nm of 
the starting material to absorbance maxima at approximately 253 nm and 293 nm observed for 
GSH adducts (Figure 4.16). 
 
 
Figure 4.16 Characteristic shift in absorbance spectra from starting material (left; red) 
with local absorbance maxima at approximately 280 nm (SECO-1 = 282.0 nm) to a GSH 
adduct (right; green; RT = 18.7 min) with two local absorbance maxima at approximately 
253 nm and 294 nm (SECO-1 = 252.4 nm and 293.9 nm). 
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NL(+) 129 and 307 scans were done to determine if aromatic or benzylic GSH adducts, 
respectively, were present. The (+) NL 129 scan indicated a precursor ion with an m/z of 608.4 
(Figure 4.17). No precursor ions were identified in the (+) 307 scans.   
 
Figure 4.17 Direct infusion ESI (+) NL 129 scan of SECO-1 oxidized with mushroom 
tyrosinase, trapped with a 5:1 GSH trapping system. 
The m/z range indicated by the NL scan (m/z 605-607) was isolated from the overall range of m/z 
100 to 700 (Figure 4.18) and compared to the HPLC chromatogram. The identified LC-MS 
peaks with RT of 10.1, 10.6, 18.0 and 18.8 min correspond with the 10.4, 10.9, 18.8 and 19.8 
min peaks respectively identified as having the characteristic shift in absorbance maximum in the 
HPLC-UV chromatogram. 
 +NL (129.00): 0.033 to 0.769 min from Sample 11 (NL 129 A1-1) of August 21, 2014.wiff (Turbo Spray) Max. 6.5e5 cps.
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Acq. Time: 10:38
Acq. Date: Thursday, August 21, 2014
Polarity/Scan Type: Positive Neutral Loss ***AB SCIEX SERVICE**
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Figure 4.18 LC-MS ESI (-) MS
1
 scan of SECO-1 after mushroom tyrosinase oxidation with 
GSH trapping system present, m/z 605-607 range isolated from overall range of m/z 100 to 
700. 
A product ion scan (m/z  = 608.3) of SECO-1 after MT oxidation in the presence of GSH was 
consistent with the suggested structure showing some of the characteristic fragmentation patterns 
of GSH by ESI (+) m/z 75, 129, 146, 232, 249 and 275 (Figure 4.19). 
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Figure 4.19 Product ion scan of a SECO-1 glutathione adduct (m/z  = 608.3) consistent with 
the suggested structure showing some of the characteristic fragmentation pattern of GSH 
in ESI (+) m/z 75, 129 and 146. 
4.2.2 No GSH trapping system 
After 1 h incubation with mushroom tyrosinase in Na2HPO4 buffer (50 mM; pH 6.0) at room 
temperature with no trapping system, SECO-1 showed multiple metabolites with similar 
retention times (Figure 4.20). None of the peaks shown in this chromatogram were observed in 
previous experiments with the NovaPak column. The solution changes from colourless to yellow 
in the absence of a GSH trapping system. SECO-3 and SECO-4 demonstrate similar metabolite 
profiles.   
 +MS2 (608.00) CE (35): 0.050 to 0.952 min from Sample 12 (+MS2 608 A1-1) of August 21, 2014.wiff (Turbo ... Max. 4.7e5 cps.
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Acq. Time: 10:42
Acq. Date: Thursday, August 21, 2014
Polarity/Scan Type: Positive Product Ion ***AB SCIEX SERVICE**
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Figure 4.20 HPLC chromatogram of SECO-1 after mushroom tyrosinase oxidation in the 
absence of GSH trapping system at  = 280 nm. None of the peaks shown in this 
chromatogram were observed in previous experiments with the NovaPak column.  
These peaks correspond to an addition in mass of 14 Da as shown by LC-MS (Figure 4.21).  
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Figure 4.21 LC-MS ESI (-) MS
1
 scan of SECO-1 after mushroom tyrosinase oxidation with 
no GSH trapping system present, m/z 314-316 range isolated from overall range of m/z 100 
to 700. 
The 14 Da difference corresponds to addition of an oxygen atom and loss of 2 hydrogens. 
 
SECO-3 and SECO-4 follow the same pattern of metabolism as SECO-1. In the presence of 
GSH, aromatic GSH adducts are formed. In the absence of GSH there is an addition of 14 Da. 
The m/z (-) and the RT (min) of the metabolites are reported in Table 4.3. SECO-2 is not 
metabolized by mushroom tyrosinase so only starting material is reported.  
 
 
 
 
 
 59 
 
Table 4.3. Summary of LC-MS data for mushroom tyrosinase oxidation of SECO 
analogues. 
Analogue Oxidation m/z (-) RT (min) NL (+) 
SECO-1 
Starting material 301 23.8 N/A 
In presence of 
GSH 
608 10.1 129 
608 10.6 129 
608 18.0 129 
608 18.8 129 
In absence of GSH 
315 22.7 N/A 
315 23.1 N/A 
315 23.5 N/A 
SECO-2 Starting material 315 24.9 N/A 
SECO-3 
Starting material 333 5.5 N/A 
In presence of 
GSH 
638 2.2 129 
638 2.5 129 
In absence of GSH 
347 2.8 N/A 
347 3.2 N/A 
347 3.5 N/A 
347 4.0 N/A 
SECO-4 
Starting material 361 22.2 N/A 
In presence of 
GSH 
666 5.1 129 
666 5.4 129 
666 8.3 129 
666 11.8 129 
In absence of GSH 
375 15.3 N/A 
375 18.8 N/A 
375 19.4 N/A 
375 21.2 N/A 
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4.3 Rat Liver Microsomes 
Rat liver microsome (RLM) oxidations were conducted to investigate the in vitro hepatic 
oxidative metabolism and bioactivation of the four SECO analogues. Oxidation was conducted 
with 0.5 mg/mL of microsomal protein, 0.5 mM of the test compound, 5 mM MgCl2, 5 mM GSH 
and 10 mM SPP in a 50 mM Na2HPO4 pH 7.4 buffer in a water bath at 37°C. The DMSO 
content was 0.5%. All SECO analogues were metabolized by RLM. In the presence of GSH, 
GSH adducts were detected. Demethylation reactions also occurred. Incubations carried out in 
the absence of NADPH and using boiled microsomes were used as negative controls. Results 
consistent with autoxidation were observed, no additional metabolism occurred.  
 
4.3.1 SECO-1 
RLM oxidation of SECO-1 formed products with RT of 10.1, 10.7, 18.0 and 19.0 min (Figure 
4.23).  
 
      
Figure 4.22 LC-MS ESI (-) MS
1
 scan of SECO-1 after rat liver microsome oxidation with 
GSH trapping system present, m/z 605-607 range isolated from overall range of m/z 100 to 
700. 
XIC of -Q1: 605 to 607 Da from Sample 11 (RLM-A1-1) of April 14, 2015.wiff (Turbo Spray) Max. 3.7e7 cps.
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Time, min
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1.0e7
1.2e7
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Acq. Time: 16:53
Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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These products corresponded to the standard GSH adducts generated by SECO-1 oxidation by 
MT with RT of 10.1, 10.6, 18.0 and 18.8 min respectively (Table 4.4). 
 
Table 4.4 LC-MS retention times of aromatic GSH adducts generated from mushroom 
tyrosinase and rat liver microsome oxidation of SECO-1 in the presence of GSH. 
SECO-1 aromatic 
GSH adduct MT RLM 
RT (min) 
10.1 10.1 
10.6 10.7 
18.0 18.0 
18.8 19.0 
 
NL (+) 129 and product ion scans were used to confirm the presence of aromatic GSH adducts.   
 
In the absence of GSH there was a decrease in starting material of approximately 34% as 
determined by HPLC. HPLC shows one potential product (RT = 1.7 min; Figure 4.24) that may 
be obscured by NADPH in the LC-MS analysis, however this product would not account for the 
total decrease. This particular chromatogram was run without an internal standard to preclude the 
possibility of it obscuring a metabolite.  
 
 
Figure 4.23 HPLC chromatogram ( = 282 nm) of SECO-1 after rat liver microsome 
oxidation in the absence of GSH. 
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No major products were detected by LC-MS, however there was weak evidence of SECO-1 
cyclization (RT = 24.7 min; Figure 4.25) by LC-MS. 
  
 
Figure 4.24 LC-MS ESI (-) MS
1
 scan of SECO-1 after rat liver microsome oxidation in the 
absence of GSH trapping system, m/z 298-300 range isolated from overall range of m/z 100 
to 700. 
The two possible cyclo-SECO-1 structures consistent with ortho-quinone formation are shown in 
Figure 4.26.  
 
                               
Figure 4.25 Possible structures of potential SECO-1 cyclized metabolites. 
XIC of -Q1: 298 to 300 Da from Sample 12 (RLM-A1-2) of April 14, 2015.wiff (Turbo Spray) Max. 1.5e7 cps.
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Acq. Time: 17:33
Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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4.3.2 SECO-2 
SECO-2 was metabolized by RLM. A precursor ion of m/z = 646.0 (Figure 4.27) was identified 
by NL (+) 307. A mass charge ratio of 646.0 corresponds to the expected m/z of a SECO-2 GSH 
adduct with the addition of a sodium ion.  
 
 
Figure 4.26 Direct infusion ESI (+) NL 307 scan of SECO-2 after rat liver microsome 
oxidation in the presence of 10:1 GSH trapping system. 
When the collision energy was increased, this precursor ion corresponded with a metabolism 
product (no sodium) with RT of 22.9 min (Figure 4.28).  
 +NL (307.00): 51 MCA scans from Sample 13 (+NL307 a2-1) of November 26, 2014.wiff (Turbo Spray) Max. 4.2e4 cps.
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Acq. Time: 10:54
Acq. Date: Wednesday, November 26, 2014
Polarity/Scan Type: Positive Neutral Loss ***AB SCIEX SERVICE**
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Figure 4.27 LC-MS ESI (-) MS
1
 scan of SECO-2 after rat liver microsome oxidation in the 
presence of GSH trapping system, ionization at 22.9 min. 
This indicates a benzylic GSH adduct (Figure 4.29).  
 
 
Figure 4.28 Structure of SECO-2 GSH adduct at the benzyl position. 
Peaks consistent with dealkylation (SECO-1), with subsequent oxidation to an o-Q and trapping 
with GSH were detected (Figure 4.30). These peaks had m/z = 606.5 and RT consistent with 
SECO-1 aromatic GSH adducts (Table 4.5). NL (+) 129 and product ion scans were attempted, 
however these products were not present in sufficient quantity for reliable results.  
 
 
 -Q1: 22.938 min from Sample 13 (RLM-A2-1) of April 14, 2015.wiff (Turbo Spray) Max. 1.3e6 cps.
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Acq. Time: 18:14
Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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Figure 4.29 LC-MS ESI (-) MS
1
 scan of SECO-2 after rat liver microsome oxidation with 
GSH trapping system present, m/z 605-607 range isolated from overall range of m/z 100 to 
700. 
 
Table 4.5 Comparison of the retention times for the SECO-1 aromatic GSH adducts and 
the suspected GSH adducts from SECO-2 dealkylation followed by oxidation and trapping 
with GSH resulting from rat liver microsome oxidation.  
RLM SECO-1 SECO-2 
RT (min) 
10.1 10.5 
10.7 10.8 
18.0 17.8 
19.0 18.7 
 
In the absence of the GSH trapping system a product with an m/z = 313.5 (Figure 4.31), ESI (-) 
with a RT = 28.5 min was detected (Figure 4.32).  
 
XIC of -Q1: 605 to 607 Da from Sample 14 (RLM-A2-2) of April 14, 2015.wiff (Turbo Spray) Max. 3.0e6 cps.
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Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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Figure 4.30 LC-MS ESI (-) MS
1
 scan of SECO-2 after rat liver microsome oxidation in the 
absence of GSH trapping system, m/z 312-314 range isolated from overall range of m/z 100 
to 700. 
 
XIC of -Q1: 312 to 314 Da from Sample 14 (RLM-A2-2) of April 14, 2015.wiff (Turbo Spray) Max. 1.9e7 cps.
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Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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Figure 4.31 LC-MS ESI (-) MS
1
 scan of SECO-2 after rat liver microsome oxidation in the 
presence of GSH trapping system, ionization at 28.5 min isolated from 40 min 
chromatograph. 
This product was consistent with what is expected for a lariciresinol-like metabolite (Figure 
4.33).   
 
 
Figure 4.32 Structure of SECO-2 lariciresinol-like metabolite 
 
There is also evidence of a dealkylated product. This metabolite would have the same structure 
as SECO-1 and has the expected m/z = 301.1 and RT = 23.8 (Figure 4.34).  
 -Q1: 28.466 min from Sample 14 (RLM-A2-2) of April 14, 2015.wiff (Turbo Spray) Max. 2.3e6 cps.
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Figure 4.33 LC-MS ESI (-) MS
1
 scan of SECO-2 after rat liver microsome oxidation in the 
absence of GSH trapping system, m/z 300-302 range isolated from overall range of m/z 100 
to 700. 
 
4.3.3 SECO-3 
Like SECO-1, SECO-3 forms aromatic GSH adducts with RT = 2.4 and 2.6 min which are 
consistent with the aromatic GSH adducts formed by MT oxidation (Table 4.6).  
 
Table 4.6 LC-MS retention times of aromatic GSH adducts generated from mushroom 
tyrosinase and rat liver microsome oxidation of SECO-3 in the presence of GSH. 
SECO-3 MT RLM 
RT (min) 
2.2 2.4 
2.5 2.6 
 
XIC of -Q1: 300 to 302 Da from Sample 14 (RLM-A2-2) of April 14, 2015.wiff (Turbo Spray) Max. 9.0e6 cps.
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
Time, min
0.0
5.0e5
1.0e6
1.5e6
2.0e6
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3.5e6
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Acq. Time: 18:55
Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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In the absence of GSH, we observed metabolites with RT = 24.9 and 25.8 min with an m/z = 331 
(Figure 4.35). These retention times do not correspond to the previously observed 
dibenzocyclooctadiene like product observed in the stability studies.  
 
 
Figure 4.34 LC-MS ESI (-) MS
1
 scan of SECO-3 after rat liver microsome oxidation in the 
absence of GSH trapping system, m/z 330-332 range isolated from overall range of m/z 100 
to 700. 
 
A m/z of 331 would be expected for cyclo-SECO-3 metabolites (Figure 4.36).  
 
             
Figure 4.35 Structures of possible SECO-3 rat liver microscome metabolism products in 
the absence of GSH that would possess a m/z = 301 in ESI (-) 
XIC of -Q1: 330 to 332 Da from Sample 16 (RLM-A3-2) of April 14, 2015.wiff (Turbo Spray) Max. 5.6e6 cps.
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Acq. Time: 20:16
Acq. Date: Tuesday, April 14, 2015
Polarity/Scan Type: Negative Q1 MS ***AB SCIEX SERVICE**
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There is weak evidence of a metabolite with a RT = 1.75 min with a m/z = 331 in the absence of 
GSH that agrees with the dibenzocyclooctadiene seen in the decomposition reactions (Figure 
26). It is difficult to confirm because the dibenzocyclooctadiene RT and that of NADPH (RT = 
1.2 min) are similar. This 1.75 min peak with m/z = 331 is also observed in the no NADPH 
control.  
4.3.4 SECO-4 
Like SECO-1 and SECO-3, SECO-4 forms aromatic GSH adducts with RT = 5.1, 5.4 and 8.4 
min which are consistent with the aromatic GSH adducts formed by MT oxidation (Table 4.7). 
The only difference is that with MT oxidation there is evidence of a GSH adduct with RT = 11.8 
min that is not observed with RLM oxidation.  
 
Table 4.7 LC-MS retention times of aromatic GSH adducts generated from mushroom 
tyrosinase and rat liver microsome oxidation of SECO-4 in the presence of GSH. 
SECO-4 MT RLM 
RT (min) 
5.1 5.1 
5.4 5.4 
8.3 8.4 
11.8 - 
 
As with SECO-2 there is evidence of dealkylation (Figure 4.37) RT = 10.5 and 17.9 min m/z = 
347 in the absence of GSH.  
 
       
Figure 4.36 Possible structures of SECO-4 dealkylation metabolites. 
In the presence of GSH we observed peaks with RT = 3.6 and 5.8 min, m/z = 652 that are 
consistent with dealkylated GSH adducts (Figure 4.38). 
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Figure 4.37 Possible structures for GSH adducts of dealkylation SECO-4 metabolites. 
 
In the absence of GSH there is evidence of a dealkylated cyclic product m/z = 345, RT = 24.7 
min (Figure 4.39) 
 
 
                                
Figure 4.38 Possible structures for cyclic dealkylated metabolites from SECO-4 RLM 
oxidation. 
Peaks consistent with two dealkylation reactions, forming SECO-3, and subsequent oxidation to 
an o-Q and trapping with GSH were detected. These peaks had m/z of 606.5 and retention times 
consistent with SECO-3 aromatic GSH adducts (Table 4.8). NL (+) 129 and product ion scans 
were attempted, for both the suspected single and double dealkylated GSH adducts, however 
these products were not present in sufficient quantity for reliable results.  
 
Table 4.8 LC-MS retention times of aromatic GSH adducts generated from rat liver 
microsome oxidation of SECO-3 compared to retention time of SECO-4 metabolism 
products the m/z = 638 in the presence of GSH. 
RLM SECO-3 SECO-4 
RT (min) 
2.4 3.0 
2.6 3.6 
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4.3.5 Summary 
Below (Table 4.9) is a summary of the retention times, m/z and NL results for the rat liver 
microsome oxidation of all of the SECO analogues. 
Table 4.9 Summary of the retention times, m/z and NL of the starting materials and the 
metabolites detected from rat liver microsome oxidation experiments. 
Analogue Oxidation m/z (-) RT (min) NL (+) 
SECO-1 
Starting material 301 23.8 N/A 
In presence of 
GSH 
608 10.1 129 
608 10.7 129 
608 18.0 129 
608 19.0 129 
In absence of GSH 
301 23.8 N/A 
299 24.7 N/A 
SECO-2 
Starting material 315 24.9 N/A 
In presence of 
GSH 
620 22.9 307 
608 10.5 - 
608 10.8 - 
608 17.8 - 
608 18.7 - 
In absence of GSH 
301 23.8 N/A 
313 28.5 N/A 
SECO-3 
Starting material 333 5.5 N/A 
In presence of 
GSH 
638 2.4 129 
638 2.6 129 
In absence of GSH 
331 1.7 N 
331 24.8 N/A 
331 25.8 N/A 
SECO-4 
Starting material 361 22.2 N/A 
In presence of 
GSH 
666 5.1 129 
666 5.4 129 
666 8.3 129 
652 3.6 - 
652 5.8 - 
638 3.0 - 
638 3.6 - 
In absence of GSH 
347 10.5 N/A 
347 17.9 N/A 
345 24.7 N/A 
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4.4 Inhibition 
All of the SECO analogues and SECO were sent to Life Technologies for P450 inhibition 
studies. IC50 values were determined using their SelectScreen® Biochemical P450 Profiling 
Services. All SECO analogues and SECO were prepared at a 100X concentration (50 mM) and 
diluted to a 3X working concentration in 100 mM potassium phosphate pH 7.4. The IC50 assay 
results are summarized in Table 4.10.  
 
Table 4.10 Summary of SECO and SECO analogue IC50 values for cytochrome P450 
isoforms CYP3A4, CYP3A5, CYP2C9 and CYP2C19  
IC50 (μM) CYP3A4 
a CYP3A4 b CYP3A5 a CYP3A5 b CYP2C9 CYP2C19 
SECO 99.2 303 61.4 396 24.6 47 
SECO-1 25.6 4.75 28.2 70.8 82.9 6.83 
SECO-2 20.7 34.6 23.4 48.5 6.04 0.424 
SECO-3 37.5 46.5 21.4 47.9 99.3 105 
SECO-4 62.5 100 45.5 135 185 114 
a = BOMCC 
b = DBOMF 
 
In cytochrome P450 inhibition assays the in vitro experimental conditions, including the choice 
of probe substrate, can have a significant impact on the results of the assay.
86
 Under the same 
assay conditions, different probe substrates may provide different results.
86
 These differences are 
most notable for the CYP3A subfamily.
86
  The interactions between CYP3A4 and its substrates 
and inhibitors are complex. The complex effects are attributed to the binding of multiple 
substrates within the active site of the enzyme.
87
 Consequently the interactions, in this case 
inhibition, observed with one probe may not be representative of those observed with other 
substrates.
87
 It is therefore recommended that two or more probe substrates are used for 
evaluation of CYP3A mediated interactions.
86,87
 The effects of different probe substrates may 
impact the accurate assessment of drug interaction potential and extrapolation from in vitro to in 
vivo.
86,87
 For this reason, two different probes, BOMCC and DBOMF, were used to determine 
the IC50 for CYP3A4 and CYP3A5. 
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5.0 Discussion 
Since the lignan skeleton remains a target for pharmacological applications, a greater 
understanding of the structural features responsible for lignan pharmacological and toxicological 
activities is necessary. Previously the structure-activity relationship of NDGA oxidative 
metabolism was investigated using NDGA analogues. Unlike NDGA, SECO has two additional 
hydroxyl groups, one at each γ position on the lignan backbone. What is not known is the effect 
of these hydroxyl groups on the oxidative metabolism of lignans. Based on the previous study
38
 
four areas of interest were identified: ortho-quinone (o-Q) formation, para-quinone methide (p-
QM) formation, cyclization to dibenzocyclooctadiene and intramolecular cyclization as a method 
of mediating toxicity 
 
A major limitation of this study was the lack of structural information from NMR analysis. There 
was not enough starting material available for scale up and the reactions did not produce enough 
individual metabolite for NMR analysis. NMR data was only collected for one product, the 
major SECO-3 autoxidation product. Despite a modest scale up and most of the starting material 
being converted to this single product there was very little product collected, less than 1 mg. This 
made for a poor signal to noise ratio in the NMR analysis. All structural information reported is 
based on MS and LC-MS data.   
 
5.1 High Performance Liquid Chromatography (HPLC) Method Development 
A challenge for HPLC analysis of SECO lignans is having a retention time sufficient to observe 
both polar and non-polar metabolites. This is important because a wide variety of metabolites are 
possible and expected. GSH addition would result in a metabolite that is more polar than starting 
material. Cyclization to a lariciresinol like metabolite or to a 6-membered ring would result in a 
metabolite that is less polar than the starting material. During the original phase of method 
development a Nova-Pak ® C18 3.9 × 150 mm column was determined to provide the optimal 
resolution and retention times for the SECO analogues. The retention time of SECO-3 (RT = 3.6 
min) was not ideal as many of the more polar metabolites, such as the GSH adducts, would likely 
elute in the solvent front. This was confirmed when metabolites were not detected in mushroom 
tyrosinase studies though a decrease in starting material was observed.  
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In January 2015 an Agilent Poroshell 120 EC-C18 4.6 × 50 mm 2.7 m column became 
available and the Nova-Pak ® C18 3.9 × 150 mm separation method was modified for the new 
column. The Agilent Poroshell 120 EC-C18 4.6 × 50 mm 2.7 m column, possessing a tighter 
particle size distribution,  showed an improved retention time for SECO-3 (RT = 5.5 min). Even 
for analogues where metabolites were detected, such as SECO-1, the resolution, separation and 
detection of metabolites was significantly improved as shown in Figure 5.1.  
 
 
Figure 5.1. Comparison of Nova-Pak ® C18 3.9 × 150 mm column (top) and Agilent 
Poroshell 120 EC-C18 4.6 × 50 mm 2.7 m column (bottom) after mushroom tyrosinase 
oxidation of SECO-1.  = 280 nm.  
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5.2 SECO Analogue Stability 
If a compound is to be used as a pharmaceutical agent it is imperative to understand its 
physiological stability. A compound with a short half-life under physiological conditions may 
not reach the site of effect. If a compound’s stability is not determined under the in vitro 
experimental conditions, incorrect conclusions as to the compounds pharmacological activity 
may be drawn. If the compound is unstable and no effect is observed it may be due to the 
absence of the compound because of decomposition and not the ability of the compound to 
produce the tested effect. Alternatively, effects attributed to the starting material may in fact be a 
result of one or more of the decomposition products. Olson et al. (2008) observed the instability 
of quercetin in Dulbecco’s modified eagle medium which was incubated under normal cell 
culture conditions.
88
 It was posited that the quercetin breakdown products were actually 
responsible for the proapoptotic effects normally attributed to quercetin.
88
 NDGA, NDGA 
analogues and flavonols, a related family of polyphenols, have all demonstrated instability in 
aqueous buffer systems.
38,89
 Therefore, the stability of the SECO analogues under physiological 
assay conditions needed to be determined. 
 
Stability studies were also useful for separating the effects of the potentially competing processes 
of autoxidation and enzyme oxidation. The half-life of the decomposition will determine if 
autoxidation will be a concern on the time scale of our experiments and to determine if 
metabolites of autoxidation products need to be considered. The half-life of the SECO analogues 
may also be an indication of whether they are suitable for future cell culture studies. The half-life 
of the compound needs to be substantially longer than the incubation period. SECO-3, whose t1/2 
= 1.73 h at pH 7.4, for example is not likely appropriate for cell culture studies, unless 
experimental conditions are utilized which minimize autoxidation.  
 
All of the SECO analogues were stable at pH 6.0 but only SECO-2, the sole phenol analogue, 
was stable at pH 7.4. The autoxidation potential of catechols and phenols is pH dependent with 
stability inversely proportional to pH.
90
 Therefore, it is reasonable that the catechol analogues are 
stable at pH 6.0 but not 7.4. In this investigation there was no evidence of phenol instability. This 
is contrary to previous research on NDGA analogues, illustrated in Figure 5.2, where phenol 
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analogue instability at pH 7.4 was observed. The half-life of NDGA analogue A2 was 5.49 h and 
the half-life of A3 was 6.70 h.
39
  
 
 
Figure 5.2 Structure of previously studied NDGA phenol analogues: A2 (left) and A3 
(right)                               
Due to the observation that analogues with a phenol substituent on the aromatic ring were stable 
and those with a catechol substituent were not, it was expected that SECO-3 with catechol 
substituents on both aromatic rings would have the shortest half-life. SECO-3 does indeed have 
the shortest half-life (t1/2 = 1.73 h) and is consistent with the previously reports for NDGA and 
NDGA analogue 6, which have catechol substituents on both aromatic rings (t1/2 = 3.94 and 1.47 
h respectively).
39
  
 
SECO-3 was the only SECO analogue where there was evidence of a dibenzocyclooctadiene 
decomposition product, consistent with the NDGA study that posited the need for catechol 
moieties on both aromatic rings for this type of cyclization to occur.
38
 The formation of and 
decomposition of the dibenzocyclooctadiene was also consistent. SECO-3 
dibenzocyclooctadiene concentration peaked at 8 h. NDGA and NDGA analogue 6 (Figure 5.3) 
both had dibenzocyclooctadiene concentration that peaked at 9 h.
39
  
 
Figure 5.3 Stucture of NDGA analogue 6 
Though the half-life of SECO-3 is consistent with those seen in the NDGA study, the t½ of 
SECO-1 and SECO-4 are longer than observed for all of the NDGA analogues. This could speak 
to a possible stabilization effect of the two hydroxyl groups in the SECO analogues when 
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cyclization to a dibenzocyclooctadiene does not occur. Since dibenzocyclooctadiene formation 
can occur in some lignans, it is possible that the lignan analogues may adopt conformations in 
solution that favour a stabilizing interaction between the alcohols and the catechols. The precise 
nature of such a stabilizing conformation however is unclear. 
 
The half-lives of SECO-1 and SECO-4 are similar but not the same. There is approximately a 2 h 
difference, which opens up the possibility that the substituents on the opposite aromatic ring 
influence the overall lignan stability. Interestingly the stability trend observed for SECO-1 and 
SECO-4 differs from that for the analogues of NDGA (NDGA-1 and NDGA-4). NDGA -1 (t1/2 
4.22 h) is more rapidly autoxidized than NDGA-4 (t1/2 4.62 h). For the SECO analogues 
analyzed using the same linear transformation it is the opposite, SECO-1 has a longer half-life 
(t1/2 = 9.00 h) than SECO-4, (t1/2 = 7.03 h). It should be noted that the NDGA calculations were 
performed using Excel, while this study used GraphPad for statistical analysis. Unexpectedly, in 
both methods of analysis, linear and non-linear regression, the SECO catechol analogues 
consistently displayed greater stability than the NDGA catechol analogues. How the alcohol 
groups on the side chain influence lignan stability is not known and will require further study. 
 
5.3 Silver Oxide Oxidation 
Silver oxide oxidation is accepted standard method of generating para-quinone methides.
91,92
 
This protocol was intended to be used to generate p-QM standards, however, the silver oxide 
oxidation experiments with the SECO analogues were not successful in producing GSH adducts. 
The silver oxide oxidation protocol was successful in generating GSH adducts for the model 
compound eugenol (Figure 5.4), which is consistent with Thompson et al., 1990.
93
  
                               
Figure 5.4 Eugenol (left) and Eugenol-SG adduct (right) formed after silver oxide 
oxidation. Adduct location determined by MS. 
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When the reaction was followed by UV-Vis spectrophotometry, a change in maximum 
absorbance from approximately 280 nm was observed to longer wavelength, approximately 350 
nm, consistent with p-QM formation.
78
 Working concentrations agreed with the eugenol pilot 
studies and should have been sufficiently dilute for solubility. Addition of the oxidation mixture 
to buffer for trapping with GSH resulted in loss of absorbance, likely as a result of insolubility, 
implying that the SECO p-QMs were excessively hydrophobic.  In an effort to overcome this 
presumed hydrophobicity, the quinone methides were extracted with ethyl acetate, however this 
was also unsuccessful. There have been consistent solubility issues with these lignans and 
ultimately the use of this method to make standards was unsuccessful. The concentrations of 
lignan used should have been sufficiently low to avoid quinone polymerization and precipitation. 
The alcohol groups may impart a unique property to the lignans and requires further 
investigation. 
 
5.4 Mushroom Tyrosinase Oxidation 
Tyrosinase (EC 1.14.18.1) is a copper-enzyme, widely distributed in nature.
94,95
 Tyrosinase 
catalyzes the hydroxylation of monophenols to ortho-diphenols and the oxidation of ortho-
diphenols to ortho-quinones, using molecular oxygen.
94,95
 Diphenols are better mushroom 
tyrosinase substrates than monophenols.
96
 Mushroom tyrosinase (MT) experiments were 
conducted to create ortho-quinone standards, as tyrosinase-catalyzed oxidation of a catechol is a 
common method for generating ortho-quinones.
78,81,91,97
  
 
SECO-2 is the only analogue that does not contain a catechol moiety and was the only analogue 
not metabolized by MT. MT is capable of carrying out an ortho hydroxylation reaction to form a 
catechol, but this was not observed in either the presence or absence of GSH. Hydroxylation may 
occur below our limit of detection. 
 
SECO-1, SECO-3 and SECO-4 all followed the same pattern of metabolism. In the presence of 
GSH, the analogues are first oxidized to ortho-quinones and then trapped with GSH (Figure 5.5). 
All of the catechols formed aromatic GSH adducts as confirmed by mass spectrometry; NL (+) 
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129 and product ion scans. There was no evidence of either cyclization or hydroxylation, 
however it is possible that cyclization and/or hydroxylation was below our limit of detection.  
 
  
Figure 5.5 Proposed reaction scheme for mushroom tyrosinase mediated oxidation of 
SECO-1 in the presence of GSH 
In the absence of the GSH trapping system SECO-1, SECO-3 and SECO-4 were metabolized to 
multiple (3, 4 and 4, respectively) metabolites that showed an addition of 14 Da to their 
respective starting material molecular masses by MS. Given the possible MT reactions, the 14 
Da addition is in accordance with cyclization and the addition of an oxygen atom. Figure 5.6 
illustrates a possible SECO-1 metabolite.  MT is capable of hydroxylating a catechol at the ortho 
position; an intial ortho-quinone that undergoes intramolecular cyclization would produce a 
catechol, which would be anticipated to be a favourable MT substrate and consistent with our 
results. 
 
 
Figure 5.6 Possible SECO-1 metabolite structure; accounts for the addition of 14 Da. 
 
Figure 5.7 illustrates two possible reaction pathways for MT oxidation in the absence of GSH 
that would account for the additional 14 Da.  
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Figure 5.7 Possible reaction schemes for the mushroom tyrosinase mediated oxidation of 
SECO-1, SECO-3, SECO-4 in the absence of GSH.  
Note that in Figure 5.7, hydroxylation is shown at one of the possible ortho positions for 
simplicity. An alternative 6-membered ring cyclization product is also possible ortho to the 
catechol OH, however based on the most reactive site in previous lignan catechols, we suspect 
that the structures as shown are the most likely.
98
 Due to the absence of hydroxylation in SECO-
2 and in the presence of GSH, cyclization most likely occurs prior to hydroxylation. For the 
proposed reaction schemes to occur, GSH addition (an intermolecular reaction) must out 
compete cyclization, an intramolecular reaction (kcyc < kGSH). Thiols are superior nucleophiles to 
alcohols, which may explain the ability of GSH to compete with intramolecular cyclization, 
although other steric or electronic factors may also contribute.   
 
5.5 Microsomal Oxidation 
5.5.1 Assay Development and Pilot Study 
Rat liver microsome experiments were carried out to investigate the in vitro oxidative 
metabolism of the SECO analogues. The development of the microsomal oxidation assay 
protocol was time consuming, as SECO is a relatively poor cytochrome P450 substrate. We first 
thought that something had occurred during microsome preparation that caused the destruction of 
P450 activity. To investigate this possibility rat liver microsomes (0.5mL; 20mg/mL; Lot# 
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RT053C) were purchased from Invitrogen (Life Technologies), which did not resolve this issue. 
Another possibility was the presence of NADPH-pyrophosphatase which degrades NADPH and 
is present in rat liver microsomes, but which is not found in human liver microsomes.
99
 The 
original protocol did not contain a NADPH-pyrophosphatase inhibitor.
99
 NADPH-
pyrophosphatase catalyzes the reaction: 
 
NADPH + H2O  NMNH + ADP 
As no NADPH regenerating system was included, the NADPH dependent-P450 reactions 
decreased, causing the metabolism of the SECO analogues to fall below our detection limits. 
NADPH-pyrophosphatase can be inhibited with the addition of sodium pyrophosphate.
99
 
Overloading the reaction with NADPH allowed for the detection of metabolism with both our 
model compound eugenol and with the SECO analogues. NADPH is over 35,000 times more 
expensive than sodium pyrophosphate, therefore sodium pyrophosphate was added to the assay 
protocol to decrease the amount of NADPH necessary for each reaction. Previous research in our 
lab did not detect the metabolism of phenols, possibly due to the absence of NADPH-
pyrophosphatase inhibition.  
 
Eugenol was used as a model compound in rat liver microsome assay protocol pilot studies. 
When eugenol was oxidized in the presence of GSH it formed a benzyl GSH adduct (Figure 5.8), 
which was consistent with the results of Thompson et al. 1990.
93
  
                                   
Figure 5.8 Structure of eugenol (left) and the structure of the eugenol benzylic GSH adduct 
(right). 
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5.5.2 Reaction Pathway 1 
Figure 5.9 illustrates the proposed RLM mediated oxidation reaction pathway 1 for SECO-1 and 
SECO-2.  
 
 
Figure 5.9 Scheme 1: Reaction pathway 1 proposed for the rat liver microsome (P450) 
mediated oxidative metabolism of SECO-1 and SECO-2 
SECO-1 has the simplest reaction pathway. In the presence of GSH, SECO-1 is oxidized to an 
ortho-quinone and trapped with GSH to form aromatic GSH adducts as determined by MS. 
These adducts agree with MT standards that were previously discussed. In the absence of GSH 
there were no major metabolism products detected. There was weak evidence of cyclization 
found (RT = 24.7 min) only detected by MS and a possible product (RT = 1.7 min) only detected 
by HPLC, however, these could not account for the decrease in starting material observed. Only 
one cyclization product (6'-position) is illustrated in Figure 5.9 for simplicity, though we 
acknowledge that the 2'-isomer is also possible as shown in Figure 4.25. One possible 
explanation for the loss of starting material to unobserved products is that SECO-1 could be 
metabolized to a dicarboxylic acid derivative that would be anticipated to elute in the solvent 
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front, and could not be characterized.
98
 Diacids are known to be generated from o-Q by reaction 
with HOO
-
 that produces a neutral diacid following acidification and isolation.
100
  
 
A benzylic GSH adduct was detected (NL (+) 307) upon SECO-2 oxidation in the presence of 
GSH. This indicates the formation of a p-QM prior to trapping. In the absence of GSH a 
metabolite with a m/z in agreement with a cyclization product was observed. Cyclization to the 
aromatic ring is also possible, with these structures shown in Figure 5.10, but given what is 
known about SECO metabolism, the lariciresinol-like cyclization is most likely and is shown in 
scheme 1.  
 
                             
Figure 5.10 SECO-2 cyclization to the aromatic ring 
In addition to oxidation to a p-QM, cytochrome P450 catalyzes a dealkylation reaction forming 
SECO-1. In the presence of GSH, metabolites with a RT and m/z that agree with the SECO-1 
aromatic GSH adducts and the SECO-1 MT standards were observed. Unfortunately, the 
conversion was low and there was not enough of these metabolites to be reliably detected using 
NL (+) 129 scans to confirm whether they were aromatic GSH adducts.    
 
5.5.3 Reaction Pathway 2 
Figure 5.11 illustrates the proposed RLM mediated oxidation reaction pathway 3 for SECO-3 
and SECO-4. 
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Figure 5.11 Scheme 2: Proposed reaction pathway 2 for the rat liver microsome mediated 
oxidative metabolism of SECO-3 and SECO-4 
SECO-3 and SECO-4 demonstrate the same basic reactions as SECO-1 and SECO-2 for RLM 
mediated oxidation: dealkylation and oxidation to a quinone. However, because of the increased 
number of substituents on the aromatic rings there exists an increased number of possible 
metabolites.  
 
In the presence of GSH, SECO-3 generated aromatic GSH adducts (NL (+) 129) that agreed with 
the previously created MT standards. In the absence of GSH, 3 metabolites were detected with 
RT of 1.7, 24.8 and 25.8 min. The 1.7 min peak is consistent with the dibenzocyclooctadiene 
decomposition product observed in the stability studies (Figure 4.9). This metabolite was 
difficult to detect in the presence of NADPH as the RT of NADPH was 1.2 min and overlaps 
with the dibenzocyclooctadiene signal. This metabolite was also detected in the no NADPH 
control and was likely a result of autoxidation and not enzyme oxidation. There are two potential 
cyclization products for SECO-3 involving the alcohol side-chain, both shown in Figure 5.11, 
that agreed with the two RT and m/z observed. What product corresponds to which elution time 
is unknown at present. Because there were multiple metabolites and because we have not 
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conducted their individual quantitation it is difficult to determine if a dicarboxylic acid was 
another potential metabolite.  
 
Oxidation of SECO-4 in the presence of GSH produced aromatic (NL (+) 129) GSH adducts 
consistent with MT generated standards. These adducts were the major metabolites detected. In 
the presence of GSH, SECO-4 metabolism also generated an additional 4 possible GSH adducts; 
two metabolites with the expected m/z for dealkylated GSH adducts and two with that of double 
dealkylated GSH adducts.  The RT of the double dealkylated GSH adducts agreed with the RT of 
the SECO-3 aromatic GSH adducts, but there was insufficient metabolite produced for NL 
confirmation.  
 
In the absence of GSH there is evidence of two single dealkylation products, RT = 10.5 and 17.9 
min. There are two possible single dealkylation products (Figure 4.35) though assigning specific 
structures a retention time is not currently possible. Conversely, there are 5 possible single 
dealkylation and cyclization metabolites (Figure 4.38), but only one product (RT = 24.7 min) 
with the predicted m/z is detected. If the catechol was oxidized to an o-Q followed by 
cyclization, multiple products would be expected. However, if dealkylation occurs in the para-
position and that phenol is oxidized to a p-QM followed by cyclization to a lariciresinol like 
product only one metabolite is expected. Therefore, only the p-QM cyclization to a lariciresinol 
like metabolite is included in Figure 5.11. Given oxidation to the p-QM, it is reasonable to 
postulate that one of the previously discussed single dealkylation GSH adducts is a benzyl adduct 
however this cannot be presently confirmed.  
 
All SECO analogues formed quinones. Catechol analogues formed o-Q and phenol analogues 
formed p-QM. There was no evidence of isomerization from an o-Q to a p-QM in any of our 
results, which is in agreement with the previous NDGA study.
38
  
 
The proposed reaction schemes are only possible if the intermolecular reaction of GSH addition 
outcompetes the intramolecular reaction of cyclization (kcyc < kGSH.). Theoretically if the 
quinones are able to react with GSH then it is possible for them to react covalently with cellular 
macromolecules such as DNA and proteins, making cyclization a poor detoxification 
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mechanism. To my knowledge this is the first time anyone has reported GSH outcompeting 
cyclization to a lariciresinol like metabolite with this class of compound. In the case of SECO-2, 
though oxidation to a p-QM was expected, addition of GSH at the benzylic position was not. 
Previous attempts at trapping SECO oxidized to a p-QM with GSH failed, generating only 
lariciresinol, which was generated as the intramolecular reaction out competed the intermolecular 
reaction of GSH addition.
2
 Rat liver microsome oxidation of SECO was repeated and the 
previously generated results were confirmed. No GSH adducts were detected and a metabolite 
consistent with lariciresinol was the major metabolite in both the presence and absence of GSH. 
No dealkylation was detected. This could be due to a difference in the cytochrome P450 isoforms 
that metabolize SECO versus the SECO analogues.  
 
5.6 Inhibition 
SECO has many potential pharmacological uses including: reduction in serum cholesterol levels, 
delaying the onset of type II diabetes, the treatment/prevention of cardiovascular diseases, and 
decreased formation of breast, prostate and colon cancers. A number of pharmaceutical drugs are 
currently used to treat these conditions such as: Docetaxel, Doxorubicin, Cabazitaxel, 
Abiraterone, Enzalutamide, Atorvastatin, Rosuvastatin, Fluvastatin, Simvastatin, Lovastatin and 
Pravastatin. All of these drugs that undergo P450 metabolized are metabolized by subfamilies 
CYP3A and CYP2C. As we were interested in studying potential drug interactions, isoforms 
CYP3A4, CYP3A5, CYP2C9 and CYP2C19 were selected for inhibition screening.  
 
The choice of probe substrate can have a significant impact on the results of an in vitro 
cytochrome P450 inhibition assay.
86
 Different probe substrates may not provide the same result, 
even when all of the other assay conditions are kept constant.
86
 These differences are most 
notable for the CYP3A subfamily.
86
 The effects of the complex interactions between CYP3A4, 
its substrates and inhibitors are attributed to the binding of multiple substrates within the active 
site of the enzyme.
87
 Consequently the effect, in this case inhibition, observed with one probe 
may not be representative of those observed with other substrates.
87
 It is therefore recommended 
that two or more probe substrates are used for evaluation of CYP3A mediated interactions.
86,87
 
For this reason, two different probes, BOMCC and DBOMF, were used to determine the IC50 for 
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CYP3A4 and CYP3A5. IC50 is the concentration of an substrate which is needed to inhibit  a 
biological or biochemical process by 50%. The effects of different probe substrates may impact 
the accurate assessment of drug interaction potential and extrapolation from in vitro to in 
vivo.
86,87
  
 
In general, the SECO analogues were mediocre cytochrome P450 inhibitors, consistent with 
previously reported lignan IC50 values.
2
 Notably, analogues with substituents on only one 
aromatic ring tended to be stronger inhibitors than those with substituents on both aromatic rings.  
 
SECO was previously reported to have an IC50 value of 373 μM.
2
 This agrees with our results 
from the CYP3A4 and CYP3A5 DBOMF IC50 assay of 303 and 396 μM respectively, which 
form a range around the previously reported CYP3A IC50. The CYP3A probe-substrate 
interactions were significant for SECO with the BOMCC assay returning IC50 values of 99.2 and 
61.4 μM.  
 
None of the SECO analogues are particularly good CYP3A inhibitors, with the exception of 
SECO-1 in the DBOMF assay against CYP3A4. Given that this is the outlier the inhibition may 
be due to probe-substrate interaction. SECO-2 was the best inhibitor of CYP2C9 and 2C19 
activity, with the IC50 of CYP2C19 in the nM range. SECO-1 was also a good inhibitor of 2C19.  
 
Some of the tested analogues (SECO-1 and SECO-2) demonstrated inhibition against various 
P450 isoforms with IC50 values in the low M to high nM range. This could translate into in vivo 
consequences including drug interactions with co-administered drugs and toxicity. SECO-1 and 
SECO-2 may be better inhibitors as they are the most lipophilic of the analogues, which could 
make them better cytochrome P450 substrates. SECO-2, the most non-polar of the analogues, is 
also the most stable of the analogues which could influence inhibition.  
 
SECO-4 was the weakest inhibitor of cytochrome P450 activity. SECO-3 is the most polar 
analogue, however, SECO-3 is less stable than SECO-4 and its stability under the specific assay 
conditions is unknown. Some of the inhibition attributed to SECO-3 may be an artifact of a 
decomposition product, such as a dibenzocyclooctadiene. The IC50 of NDGA against CYP3A is 
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reported to be 97.3 M whereas the IC50 of dibenzocyclooctadiene is 36.8 M.
2
 The 
dibenzocyclooctadiene is the better inhibitor. Enterolactone, a mammalian lignan whose 
structure is shown in Figure 2.5, has phenol substituents on both aromatic rings. It like SECO-3 
and SECO-4 is a poor inhibitor of CYP3A.
2
 This trend points towards lignans with substituents 
on both aromatic rings being poorer inhibitors of cytochrome P450 activity than those with 
substituents on only one ring.  
 
Moclobemide is used to treat depression and social anxiety and is a known in vivo CYP2C19 
inhibitor with clinical significance.
101,102
 Moclobemide, as shown in Figure 5.11, shares certain 
structural characteristics with SECO-2 that may be relevant.  
 
                       
Figure 5.12 Structures of SECO-2 (right) and moclobemide (left) 
CYP2C19 polymorphisms are known to cause large differences in the pharmacokinetics of a 
number of clinically important drugs.
103
 Inhibition of CYP2C19, especially in poor metabolizers, 
can have clinically relevant consequences. For instance, phenytoin plasma concentrations and 
toxicity has been shown to increase and increased risk of toxicity from tricyclic antidepressants 
is likely.
101
  
 
Though there has been a limited number of studies on the endogenous role of CYP2C19, it has 
been shown to be involved in the metabolism of endogenous steroid hormones including: 
estrone, estradiol, progesterone and testosterone.
104
 This study does not suggest inhibition on the 
level of clinically relevant inhibition of metabolism of endogenous steroid hormones in an adult 
human. However, a tentative link between CYP2C19 metabolism and fetal brain development 
and adult personality, depression in particular, has been drawn.
105-108
 The impact of an inhibitor 
of CYP2C19 on a fetus undergoing brain development that is already a poor metabolizer is 
unknown.  
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6.0 Conclusions 
Quinones are a class of compounds that can have various toxicological effects in vivo, including 
cytotoxicity, immunotoxicity, and carcinogenesis. All of the SECO analogues tested formed 
quinones. Phenol analogues were metabolized to para-quinone methides (p-QM) and catechol 
analogues to ortho-quinones (o-Q). There was no evidence of isomerization from o-Q to p-QM. 
Interestingly GSH conjugation was competitive with intramolecular cyclization. In the presence 
of GSH no cyclization products were detected. To the best of my knowledge this is the first time 
GSH addition has been reported to be competitive with intramolecular cyclization in this class of 
lignan. As these quinones react with GSH it is a possibility that these quinones will react with 
cellular macromolecules such as DNA and proteins in a cellular environment leading to toxicity.  
 
Based on our results cyclization to a lariciresinol (klar) is more likely to occur than cyclization to 
a 6-membered ring (kring). This may be because klar > kring. Lariciresinol-like cyclization 
decreases the chances of phenol toxicity in vivo, however, due to dealkylation to a catechol and 
GSH out competing cyclization, it does not preclude the possibility. Based on these results, 
design of lignans that can undergo side-chain cyclization is a poor mitigation strategy for 
quinone-mediated toxicity from this class of lignan.  
 
Dibenzocyclooctadiene formation requires the presence of catechol moieties on both 6-
membered rings of the lignan, in agreement with previous studies on NDGA and its analogues. 
This process was not enzyme mediated but instead a result of autoxidation. Indeed, P450 
oxidation appears to have resulted in ortho-quinone formation and minimized 
dibenzocyclooctadiene formation. This observation provides further support for a radical-
mediated, rather than ortho-quinone-mediated, mechanism for spontaneous 
dibenzocyclooctadiene formation.
38, 39
 
 
Every SECO analogue and SECO itself demonstrated inhibition against all tested cytochrome 
P450 isoforms. Those with substituents on both aromatic rings tended to be poorer inhibitors 
than those with substituents only on one. The IC50 results for SECO inhibition of CYP3A agree 
with previously reported results. Some of the analogues demonstrated inhibition with IC50 values 
in the low M to high nM range against some of the P450 isoforms. This may translate into in 
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vivo effects especially with concerns of drug interactions with potential co-administered drugs 
such as Docetaxel and Doxorubicin. If lignans from this class of compound are to be developed 
for pharmaceutical use P450 inhibition testing will be an important component of safety 
assessments.  
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7.0 Future Research 
The major shortcoming of the metabolite study was the inability to obtain sufficient product to 
confirm the structures by NMR. More of the SECO analogue starting materials could be made so 
the assays performed in this study could be scaled up with the hope of gathering NMR data to 
confirm the structures of the metabolites suggested by MS. Even with scale up it may be difficult 
to collect enough of some of the metabolites detected as the conversion is low so preparation of a 
synthesized standard may be necessary for some of the metabolites, especially for cyclization 
products. This will be especially helpful for metabolites generated in the absence of GSH, as no 
standards were generated for these metabolites. It would be of particular interest to determine 
where cyclization occurs after a single SECO-4 dealkylation.  
The loss of starting material in the autoxidation studies also requires further study. The formation 
of diacid metabolites which elute rapidly by HPLC is anticipated, which will require further 
optimization of HPLC parameters.   
 
The specific cytochrome P450 isoforms responsible for the metabolism of SECO and the SECO 
analogues could be identified. This could elucidate a possible explanation for the different 
pattern of metabolism observed between SECO and the analogues. This could be carried out 
using supersomes. 
 
The formation of quinones infer toxicity, however toxicity studies using for example HEPG2 or 
isolated hepatocytes would provide support for this hypothesis. It is anticipated that lignan 
stability would be inversely correlated to toxicity, although lignan stability in the study 
conditions would also need to be confirmed. 
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94. Fenoll LG, Rodrıǵuez-López JN, Varón R, Garcı́a-Ruiz PA, Garcı́a-Cánovas F, Tudela J. 
Kinetic characterisation of the reaction mechanism of mushroom tyrosinase on 
tyramine/dopamine and l-tyrosine methyl esther/l-dopa methyl esther. The International 
Journal of Biochemistry & Cell Biology. 2002;34:1594-1607. 
95. Espín JC, Varón R, Fenoll LG, et al. Kinetic characterization of the substrate specificity 
and mechanism of mushroom tyrosinase. European Journal Of Biochemistry. 
2000;267:1270-1279. 
96. Yada RY, Jackman RL. Protein Structure-Function Relationships in Foods. Springer US; 
2012. 
97. Bolton JL, Acay NM, Vukomanovic V. Evidence that 4-allyl-o-quinones spontaneously 
rearrange to their more electrophilic quinone methides: potential bioactivation 
mechanism for the hepatocarcinogen safrole. Chemical Research in Toxicology. 
1994;7:443-450. 
98. Billinsky JL, Marcoux MR, Krol ES. Oxidation of the Lignan Nordihydroguaiaretic 
Acid. Chemical Research in Toxicology. 2007;20:1352-1358. 
 99 
 
99. Sasame HA, Gillette JR. The inhibitory effects of endogenous NADPH-pyrophosphatase 
on the reduction of cytochrome c and the oxidation of drugs by liver microsomes. 
Archives of Biochemistry and Biophysics. 1970;140:113-121. 
100. Witham AA, Beach DG, Gabryelski W, Manderville RA. Hydroxyl Radical-Induced 
Oxidation of a Phenolic C-Linked 2′ -Deoxyguanosine Adduct Yields a Reactive 
Catechol. Chemical Research in Toxicology. 2012;25:315-325. 
101. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS drug reviews. 
2003;9:97-140. 
102. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of 
CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clinical 
Pharmacology & Therapeutics. 1995;57:670-677. 
103. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 
2C19 genetic polymorphism. Clinical Pharmacokinetics. 2002;41:913-958. 
104. Presson A, Ingelman-Sundberg M. Pharmacogenomics of Cytochrome P450 Dependent 
Metabolism of Endogenous Compounds: Implications for Behavior, Psychopathology 
and Treatment. Journal of Pharmacogenomics & Pharmacoproteomics. 2014;5:127. 
105. Ishii G, Suzuki A, Oshino S, Shiraishi H, Otani K. CYP2C19 polymorphism affects 
personality traits of Japanese females. Neuroscience letters. 2007;411:77-80. 
106. Yasui-Furukori N, Kaneda A, Iwashima K, et al. Association between cytochrome P450 
(CYP) 2C19 polymorphisms and harm avoidance in Japanese. American Journal of 
medical genetics. Part B, Neuropsychiatric Genetics. 2007;144b:724-727. 
107. Sim SC, Nordin L, Andersson TM, et al. Association between CYP2C19 polymorphism 
and depressive symptoms. American Journal of Medical Genetics. Part B, 
Neuropsychiatric Genetics. 2010;153b:1160-1166. 
108. Farmer RF, Seeley JR. Temperament and character predictors of depressed mood over a 
4-year interval. Depression and Anxiety. 2009;26:371-381. 
 
  
 100 
 
9.0 Appendix A 
Analogues that were determined to be unstable, SECO-1, -3 and -4 at pH 7.4 were also analyzed 
using a non-linear regression analysis fitted to a phase 1 decay model prior to the linear 
transformation. Individual trials fit the model well with R
2
 values > 0.97. Figure 29 shows a 
representative graph of a SECO-4 trial at pH 7.4.  
 
 
Figure 9.1 Chemical degradation profile of SECO-4, in 50 mM Na2HPO4 pH 7.4 at 37°C 
over time (h). Change in concentration was determined from the peak area under the 
curve, normalized to the internal standard (KA-1-09-2) and plotted as a function of time 
(h).  Data was fitted to a phase 1 decay model, R
2
 = 0.99. 
 
All four trial replicates were considered for statistical analysis using a non-linear regression fit to 
a phase 1 decay model (Figure 30).  
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Figure 9.2 Chemical degradation profile of SECO-1, -2, -3 and -4, in 50 mM Na2HPO4 pH 
7.4 at 37°C over time (h). Change in concentration was determined from the peak area 
under the curve, normalized to the internal standard (KA-1-09-2) and plotted as a function 
of time (h). Curves plotted using data from 4 trials. Error bars represent +/- Standard 
Error (SE).  
 
Table 5 depicts a summary of the kinetic parameters of the unstable SECO analogues (1, 3 and 4) 
calculated using a non-linear regression fit to a phase 1 decay model. 
 
Table 9.1 Summary of kinetic data for SECO analogue autoxidation at pH 7.4 using a 
normalized data fit to a phase 1 decay model. 
 SECO-1 SECO-3 SECO-4 
k (h-1) 0.08 0.25 0.07 
t1/2 (h) 8.30 2.74 9.49 
R2 0.88 0.99 0.833 
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